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Anticoagulants are used as the first line therapy for management and prevention of 
thrombotic disorders. Thrombin and factor Xa have been the prime targets for regulation of 
the coagulation cascade. 
In this work, a small library of 17 benzofuran derivatives were synthesized and screened 
against thrombin and factor Xa. The derivatives that displayed inhibitory potential were 
docked on the exosite-II of factor Xa using a docking protocol that was developed in our 
research group. These compounds were based on the β-5 structural unit found in the 
oligomer ‗CDSO3‘, which was prepared in our lab and was found to inhibit both thrombin 
and factor Xa by an exosite-II mediated allosteric disruption of the catalytic triad.  
  xiii 
The results revealed that these β-5 like derivatives are inhibitory against thrombin and 
factor Xa, although their potency is weak. Thrombin and factor Xa appear to recognize 
different structural features suggesting a significant selectivity in recognition. Furthermore, 
a slight preference for the benzofuran scaffold was observed with factor Xa. Probing the 
mechanism of inhibition using Michaelis-Menten kinetics reveal that these compounds 
display uncompetitive inhibition of these proteases and the mechanism of inhibition is 
allosteric.  
Docking of these compounds on factor Xa were done using GOLD (Genetic algorithm for 
ligand docking) and the results, explain the observed inhibition profile. The computed 
docked poses also give an idea of the residues on the exosite-II of factor Xa critical for 
inhibition. 
The molecules studied here are radically different in terms of structure and mechanism of 
inhibition from any other ligand described in literature. This represents an opportunity to 
discover novel molecules with a possibly different pharmacological and toxicological 
profile.       
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Chapter 1  Introduction 
 
1.1 The cell based model of coagulation  
Blood coagulation is a self defense system preventing excess loss of blood and 
infiltration of microbes following injury. The initial model of the coagulation cascade 
was proposed in 1960
1, 2
 and recently a cell based model was proposed. The cell based 
coagulation cascade is proposed to occur by three steps – initiation, amplification and 
propagation
3-5
(Figure 1). 
Cell surfaces localize the activation of coagulant factors, so that systemic activation of 
the factors is prevented. Exposure of the transmembrane tissue factor (TF) is how 
coagulation is initiated in vivo in response to a vascular injury
6
. The exposed TF binds to 
factor VIIa to form the extrinsic tenase complex, which activates factor X and factor IX
7
. 
Activated factor X (fXa) activates factor V (fVa) and converts sufficient amounts of 
prothrombin to thrombin to amplify the cascade and move the site of action from TF 
bearing cells to platelet surfaces
8
. On the platelet surface fIXa binds to fVIIIa to form the 
intrinsic tenase complex which activates fX, which binds to fVa and forms the 
prothrombinase complex. This complex efficiently converts prothrombin to thrombin. 
Thrombin converts fibrinogen to fibrin monomers and activates fXIIIa which cross links 
the fibrin monomers and stabilizes the clot
9
. 
 
  2 
Figure 1 The coagulation cascade. The endogenous regulators of the cascade 
include antithrombin (AT), tissue factor pathway inhibitor (TFPI) and activated protein C 
(APC). HMWK: high molecular weight kininogen, TM: thrombomodulin, TM:IIa: 
thrombomodulin-thrombin complex, TF: tissue factor, PL: phospholipid, F: fibrin, Fm: 
fibrin monomers. (Figure was adapted from Henry, B. L.; Desai, U. R. Recent research 
developments in the direct inhibition of coagulation proteinases--inhibitors of the 
initiation phase. Cardiovasc. Hematol. Agents Med. Chem. 2008, 6, 323-336).  
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1.2 Regulation of coagulation 
Several endogenous proteins regulate the procoagulant response and prevent hyper–
coagulation by inhibiting the cascade at multiple points.  
TFPI has a role in modulating the formation of the extrinsic tenase complex
10
. First TFPI 
binds to fXa forming TFPI/fXa complex. This complex binds to fVIIa in the TF/VIIa 
complex thereby regulating its catalytic activity. Also TFPI potentiates the activity of 
heparins. 
Activated protein C (APC); in the protein C pathway, thrombin binds to 
thrombomodulin, a receptor in the endothelium
12
. On binding, thrombin activates protein 
C which inactivates fVa and fVIIa.     
 Antithrombin (AT) regulates thrombin, fIXa, fXa and also TF/VIIa complex
11
. Heparin 
induces a massive 300 – 4000 fold increase in the rate of inhibition of the target proteases 
by AT. 
 
1.3 Thrombin and Factor Xa 
Thrombin and factor Xa are the most important proteases in the coagulation cascade. 
Both the pharmaceutical industry and academia are actively involved in the design and 
development of molecules which target either one of these two proteases. The X-ray 
crystal structure of these proteases provides a useful starting point for rational design of 
their inhibitors.   
  4 
Figure 2A The topology of Thrombin. All the important domains are highlighted. 
(Figure was made in SYBYL 8.1 from the protein structure 1XMN)  
 
 
Figure 2B  The topology of fXa. (Figure was made in SYBYL 8.1 from the protein 
structure 1HCG) 
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1.3.1 The structure of Thrombin 
Thrombin is a serine protease which is similar to trypsin and chymotrypsin. It has 2 
polypeptide chains; A (36 residues) and B (259 residues) linked by disulfide bridges 
(Figure 2A). Physiologically it cleaves fibrinogen to fibrinopeptides A and B which are 
cross linked by fXIIIa to form clot. A large number of structures of thrombin have been 
deposited in the protein data bank
146
. The enzyme is organized around 2 adjacent β-
barrels in chain B and the active site residues Ser
195
, His
57
and Asp
102
 (chymotrypsinogen 
numbering) is located between them. The active site is surrounded by the 60 and the γ-
loops that restrict accessibility to the active site nucleophile
14-17
. The nomenclature given 
by Schechter and Berger has been used in literature
18
. Here substrate residues are termed 
P (for peptide) and the residues of the interacting proteases are called S (for subsite). 
Substrate residues that extend toward the N terminus of the scissile bond are numbered 
P2, P3… and substrate residues which extend toward the C terminus are termed P2‘, P3‘ 
…(Figure 3) 
 
Figure 3 Schechter and Berger nomenclature for naming subsites (S) on a 
protease and positions (P) on a polypeptide substrate. 
P1P2 P1' P2' P3'P3
S1S2 S1' S2' S3'S3
N-terminus Cleavage point C-terminus
substrate peptide
enzyme subsites
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The subsites and interacting domains present in thrombin are    
The S1 site has Asp
189
, which is present in the bottom that recognizes 
substrates/inhibitors with a basic P1 group. Also the Ser
195
, His
57
, Asp
102
 catalytic triad 
and an oxyanion hole are present. The active site is buried inside a canyon due to the 
presence of 60 and γ-insertion loops that are not present in chymotrypsinogen. 
The S2 site has the residues Tyr
60
A and Trp
60
D that create the S2 pocket which 
recognizes lipophillic P2 groups. Proline binds better in the S2 pocket. 
The S3 site is created by the side chains of Leu
99
, Ile
174
 and Trp
215
. It interacts with the 
hydrophobic group P3 and is more acidic when compared to other serine proteases due to 
a Glu at 192. 
The S4 site aliphatic residues show a preference for the S4 pocket. 
The S1’, S2’ and S3’ sites recognize hydrophobic residues P1‘, P2‘, P3‘. 
60 and the γ-insertion loop; the active site is buried in a narrow cleft made of the 60 and 
the γ-insertion loop. The residues which make the 60 loop are more hydrophobic, 
whereas the γ-insertion loop is hydrophilic and flexible. These both loops play a major 
role in substrate specificity. 
Two basic domains are present approximately 10-20Å away from the active site on 
opposite ends. The first one located to the east of the active site is Exosite-I, which 
consists of residues Lys
21
, Arg
62
, Arg
68
, Arg
70, 
Tyr
71, 
Arg
73
, Lys
106
 and Lys
107
. This site is 
involved in the binding of fibrinogen, fibrin and coagulation factors V, VIII and XIII and 
interacts with residues which are toward the N terminus of the substrate. The positive 
  7 
field created by this site provides electrostatic steering and pre-orientation for 
substrates
19
. 
The Exosite-II is located towards the west of the active site and is the more 
electropositive region
19
. Acidic molecules like glycosaminoglycans bind to this site and 
the primary residues present in this site are His
91
, Arg
93
, Arg
101
, Arg
126
, Arg
165
, Lys
236 
and 
Lys
240
(Figure 4A). These residues play a crucial role in interaction of thrombin with 
heparin. Also not every residue present in the exosite are significant for any interactions 
that occur on the site.  
Thrombin utilizes both exosite-I and II for molecular recognition
21,22
. Anionic molecules 
bind to either of the sites exclusively. The specificity of these molecules towards exosites 
depend on their ionic charge. For exosite-I, hydrophobic contacts provide most of the 
binding energy and electrostatics are involved in orienting the complementary 
hydrophobic surfaces. Example: Hirudin which is an exosite-I ligand for thrombin, 20% 
of the binding energy originates from ionic interactions
23-26
, whereas exosite-II 
interactions are primarily ionic in nature. Example: for heparin-thrombin interactions, 
80% of the binding energy is ionic
27
. It has been reported that both the exosites modulate 
the binding of each other based on changes of fluorescence of fluorescein-FPR-thrombin 
on binding with peptides
28
   but, Bock et al. have reported no change in KD values upon 
binding of these peptides
29
.  
The binding of ligands to both of the exosites induces conformational changes in the 
active site
30, 31
. This changes the specificity and reactivity of thrombin towards 
macromolecular substrates. Exosite-I ligands influence the catalytic efficiency (kCAT/KM) 
  8 
of thrombin towards hydrolysis of peptide substrates
31-33
, whereas exosite-II ligands like 
GAG‘s have no influence on the catalytic efficiency of peptide hydrolysis34, 35. However, 
allosteric modulation of the catalytic triad through exosite-II has been observed by 
chemo-enzymatically prepared lignin derivatives
36, 37
.     
Sodium binding site; The Na
+ 
binding site is located to the center of the 222 loop, which 
is situated behind the S1 specificity pocket near Asp
189
. The Na
+
 ion is coordinated 
octahedrally by carbonyl oxygens or Arg
221
A and Lys
224
 and by four internal water 
molecules. This is further stabilized by the negative charges Asp
221
 and Asp
222
. Sodium is 
an important allosteric modulator of α-thrombin. Two allosteric states have been 
characterized kinetically in absence and presence of the Na
+
 ion – the slow and the fast 
form. The fast form displays procoagulant, prothrombotic and prosignalling properties 
whereas the slow form exhibits more anticoagulant properties
38-40
.   
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Figure 4A Exosite-II of thrombin (Figure was created in SYBYL 8.1 from protein 
structure 1XMN) 
 
 
Figure 4B Exosite-II of fXa (Figure was created in SYBYL 8.1 from protein 
structure 1HCG) 
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1.3.2 The structure of Factor Xa 
Factor Xa is structurally similar to the other trypsin like serine proteases in the 
coagulation cascade. It is a Vitamin K–dependent glycoprotein that is synthesized from 
the liver and is secreted into the blood as a zymogen
97
. The mature circulating form of 
factor X has a light chain (139 residues) and a heavy chain (303 residues) held together 
by a single disulfide bond. For activation a specific argininyl – isoleucyl (Arg52-Ile53) is 
cleaved in the N-terminal of the heavy chain resulting in fXa (390 residues). The new N-
terminal Ile folds into the interior of the protein and forms ion pair with an Asp residue 
near the active site Ser
195
(Figure 2B).   The first structure of fXa determined by X-ray 
crystallography was in 1990 (PDB code 1HCG)
98
.  
The various functional domains in fXa are: 
Active site S1; where the heavy chain has the residues of the catalytic triad: Ser
195
, His
57
, 
Asp
102
 (chymotrypsinogen numbering). The overall folding resembles thrombin. The 
absence of the thrombin Tyr60A – Thr60I insertion loop makes the catalytic triad more 
accessible to substrates and inhibitors. Therefore the active cleft is described as more 
open and groove–like, when compared to the canyon–like cleft in thrombin. An Asp189 is 
present in the base of the S1 pocket which recognizes Arg like residues in the P1 site of 
substrates and inhibitors. A hydrophobic ―disulfide pocket‖ is found adjacent to S1 
formed by Gln
192
, Cys
191
, Cys
220
 and Gly
218. This has been otherwise termed as the ―ester 
pocket‖ due to accommodation of such groups in co – crystallization experiments99100.   
S2 subsite; here a Tyr
99
 side chain obstructs the S2 pocket in fXa and thereby only small 
aliphatic residues like glycine can interact. 
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S3 subsite; here an amide group of the conserved Gly
216
 can provide hydrogen–bonding 
interactions with the P3 part of a substrate/inhibitor. 
S4 subsite, where the residues Tyr
99
, Trp
215 
and Phe
174
 form an aromatic box that serves 
as the S4 subsite. Moreover, the carbonyl groups of Lys
96
, Glu
97
 and Thr
98
 form a cation 
hole at the back of the aromatic box. Aromatic interactions in the S4 pocket are crucial 
for the design of inhibitors that are selective to fXa over thrombin. 
Exosite-1 is the region in fXa that corresponds to the fibrinogen recognition exosite in 
thrombin encompasses Asn
35
-Phe
41
 and Asp
70
-Ala
81
. Whereas this region in thrombin is 
decorated with basic residues, in fXa has eight acidic groups with only one Ala. This 
region in fXa is crucial for prothrombin recognition and does not recognize fibrinogen or 
other exosite-I inhibitors of thrombin
101
.  
Exosite-II; Of the eleven basic residues seen in the exosite-II in thrombin, seven are 
found to be conserved in fXa. These residues are Arg
93
, Lys
96
, Arg
125
, Arg
165
, Lys
169
, 
Lys
236
 and Arg
240
 (chymotrypsinogen numbering). This region is otherwise called as the 
―Heparin binding Exosite‖. This region is found towards the west of the active site on 
exposed surface loops (Figure 4B). Full length high affinity heparin can interact with this 
site to produce ~200-300 fold greater acceleration of the reaction with antithrombin. 
Additionally, residues in this site have been implicated in binding of fXa with fVa and 
formation of the prothrombinase complex
101,102
.  
Ca
2+
 binding site; fXa has a three Ca
2+
 binding sites. There is one on the N-terminus Gla 
domain which is required for binding to fVa in the prothrombinase complex. The other 
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two sites are on the epidermal growth factor – like domain (EGF-1) and the C-terminal 
catalytic domain, which includes conserved loop spanning residues 70 – 80103-105.  
Na
+
 binding site; the 225 loop in fXa has been identified as the sodium binding site 
which is similar to thrombin. Studies in which the residue Tyr
225→Pro, displayed that 
specific binding of Na
+
 to this loop increases the catalytic activity of fXa towards small 
synthetic substrates and antithrombin
106,107
.  
Furthermore, it has been shown that there exists an allosteric linkage between the Na
+
 
binding loop and the Ca
2+
 binding (Glu
70
-Glu
80
) that modulates the structure and function 
of fXa
108
. 
 
1.4 Rationale for inhibition of thrombin and fXa 
 Thrombin is the final serine protease involved in the coagulation cascade. It converts 
fibrinogen to fibrin and activates factor XIII which cross links the fibrin monomers. 
Thrombin amplifies its own generation by activation of factor VIII and factor V which 
are cofactors for the intrinsic tenase and prothrombinase complex and also by indirectly 
activating factor IX - the enzyme constituent of the intrinsic tenase. Additionally 
thrombin acts as a potent platelet agonist. By recruiting platelets to the site of vascular 
injury, these activated platelets further add to thrombin generation. With this significant 
role in thrombosis and hemostasis, thrombin is a major point for inhibition in the cascade 
(Figure 5). Moreover, data from clinical trials with direct thrombin inhibitors indicate 
that short term and long term inhibition of thrombin is both safe and effective
41, 42
.  
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Factor X can be activated by the contact pathway or by the tissue factor/VIIa pathway. 
Thereby initiation of coagulation by either pathway in response to any vascular injury 
activates factor X to fXa. So, pharmaceutically it is a desired intervention point in the 
development of anticoagulants
109
. The activated factor X with its cofactor fVa combine 
on anionic surfaces (phospholipid membranes) to form the prothrombinase complex 
which converts prothrombin to thrombin.  
Factor X deficiency manifests as severe bleeding diatheses. Patients display very low 
antigen and activity levels of fXa. A number of variants of fXa deficiency suggested that 
factor X activity levels must be less than 5% of normal to display bleeding tendencies
110-
112
. This proved that activity of factor X can be suppressed distinctly without affecting 
hemostasis. Thus an ideal anticoagulant could stop thrombosis without causing systemic 
hypocoagulation.  
Studies carried out by Eisenberg et al. showed that fXa in thrombi is enzymatically active 
and was able to convert prothrombin to thrombin
113-114
. Also, fXa is accountable more 
than thrombin for clot associated procoagulant activity. The procoagulant activity of 
thrombi is due to the de novo conversion of prothrombin to thrombin and not due to 
circulating thrombin. These data suggest that in thrombi fXa is active and direct 
inhibition of thrombus associated fXa would be an effective approach to prevention of 
thrombus growth
115
.  
  14 
Figure 5 A simplified scheme of the coagulation cascade. The intervention point 
for fXa and fIIa inhibitors is shown (Figure was adapted from Leadley, R. J.,Jr 
Coagulation factor Xa inhibition: biological background and rationale. Curr. Top. Med. 
Chem. 2001, 1, 151-159).        
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1.5 Inhibitors of Thrombin 
1.5.1 Indirect inhibitors 
These molecules exploit an intermediate physiological protein to inhibit the procoagulant 
protease. 
1.5.1.1 Heparin and its derivatives 
Unfractionated heparin (UFH) is an acidic linear polysaccharide composed of alternating 
1-4 linked uronic acid and glucosamine residues (Figure 6). It has a MW of ~15000 Da. 
Low molecular weight heparins (LMWH) are produced or fractionated from UFH by 
chemical or enzymatic depolymerization techniques
43
. They usually retain a structure 
similar to UFH although the different methods used in their preparation increase their 
structural heterogeneity. UFH is the strongest acid in human physiology due to the 
presence of numerous sulfates and carboxylates that span the saccharide chain (~3.7 
negative charges per disaccharide). The pentasaccharide sequence, which is composed of 
5 residues DEFGH, mediates the interaction with antithrombin (Figure 7). Antithrombin 
(AT), a serine protease inhibitor (SERPIN), is a plasma glycoprotein which inhibits its 
target proteases by a serpin mouse trap mechanism. It uses its P1-P1‘ residues in its 
reactive center loop (RCL) to bind to the target serine protease. After binding of the 
protease to the RCL of AT to form a Michaelis - Menten complex (E:AT), the scissile 
bond P1-P1‘ is cleaved to form an acyl-enzyme intermediate(E-AT), which rearranges to 
disrupt the catalytic triad of the enzyme (E
*
-AT
*
). A competing pathway called the 
substrate pathway may operate in parallel where in mutational changes in AT may cause 
hydrolysis of the acyl – enzyme intermediate (E-AT) to yield an active enzyme (E) and a 
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cleaved inhibitor (ATC) (Figure 8).  The target proteases for AT are fIIa, fXa, fIXa. In 
presence of heparin, the inhibition rate constants of AT for these proteases increase 10
2
-
10
6
 fold
11, 44
. 
AT inhibits the procoagulant proteases by two separate mechanisms. The first one is the 
allosteric activation of AT by the sequence DEFGH. After recognition of the 
pentasaccharide sequence by AT, a change in conformation of the partially inserted RCL 
occurs
11,45,46
. This induces an accelerated cleavage of the RCL and explains the rate 
acceleration of fXa inhibition by ~300 fold in absence of Ca
2+
. 
Inhibition of thrombin by AT in presence of UFH is by the bridging mechanism. Binding 
of AT to the UFH chain is followed by thrombin binding at non-specific positions along 
the polysaccharide chain. Thrombin then diffuses along the chain to form the Michealis - 
Menten complex (E:AT), resulting in a 10
2
-10
6 
fold increase in the inhibition rate 
constants
27
 (Figure 9). LMWH and the pentasaccharide sequence by itself cannot inhibit 
thrombin as the minimum chain length of ~18 residues is required for the bridging 
mechanism
44, 47
.  
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Figure 6 General structure of heparin (Figure adapted from Henry, B. L.; Desai, 
U. R. Recent research developments in the direct inhibition of coagulation proteinases--
inhibitors of the initiation phase. Cardiovasc. Hematol. Agents Med. Chem. 2008, 6, 323-
336).   
 
 
 
Figure 7 The pentasaccharide binding sequence. 
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Figure 8 A model of the antithrombin inhibition mechanism (Figure is adapted 
from Desai, U. R. New antithrombin-based anticoagulants. Med. Res. Rev. 2004, 24, 151-
181).  
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Figure 9 The mechanism of how procoagulant proteases are inhibited by full 
length heparin (Figure is adapted from Desai, U. R. New antithrombin-based 
anticoagulants. Med. Res. Rev. 2004, 24, 151-181).  
.  
 
 
1.5.1.2 Warfarin 
Warfarin is an indirect oral anticoagulant that inhibits vitamin K dependent post 
translational modification of glutamic acid to γ-carboxyl glutamic acid, which are present 
on the N terminus of Vitamin K dependant proteins eg: factor II, VII, IX and protein C, S 
and Z
48
 (Figure 10). 
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Figure 10 The structure of warfarin. 
O O
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O
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1.5.1.3 Limitations of indirect anticoagulants 
All anticoagulants pose an excessive risk for bleeding. UFH can cause heparin-induced 
thrombocytopenia (HIT), which is a significant drop in platelet count that happens 
between 4-14 days of therapy
49
. HIT has been classified into two; Type 1 and Type II. 
The type II HIT is the most severe and is characterized by the development of antibodies 
against heparin-platelet factor 4 (PF4) complex
50
. Platelet factor 4 is a protein found on 
platelets and interacts with heparin to from a tetrameric complex. Once the heparin-PF4 
complex is formed it is recognized by antibodies on the platelet surface. In due course, 
these platelets form a thrombus effectively being removed from circulation
51
. Usually, 
the majority of HIT episodes occur with UFH, although cases with LMWH are also 
reported
52
.  Additionally, UFH displays significant intra- and inter-patient dose 
variability. Moreover, heparins do not neutralize clot bound thrombin, which increases 
the possibility of reactivating clotting at a later time
53, 54
. 
In 2007-2008, reports of serious allergy and hypersensitivity-type reactions surfaced 
following the use of UFH resulting in at least 81 cases of death. Investigations revealed 
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that the UFH used was contaminated with oversulfated chondroitin sulfate (OSCS) and 
the source originated in China. It is not sure whether the contamination was intentional or 
due to faulty processing of pig intestines
55, 56
.     
Warfarin suffers from a narrow therapeutic index and many drug–drug or drug–food 
interactions. Clinically used warfarin is a racemic mixture of R- and S- enantiomers, with 
the R- enantiomer being more active. However it is metabolized more quickly than the S- 
enantiomer. Single nucleotide polymorphisms (SNP‘s) in the gene encoding the enzyme 
that metabolizes S- warfarin have been found which translate to significantly enhance 
anticoagulation effect
57-60
. From 1990 to 2000, warfarin was ranked in the top ten for the 
most number of serious and adverse events received by the FDA. Also in 2006, a ―black 
box‖ warning was placed on warfarin by FDA related to its high risk of bleeding61, 62.     
 
1.5.2 Direct Thrombin Inhibitors (DTI) 
These molecules inhibit thrombin directly either through the active site or by an allosteric 
mechanism of action. A major advantage of DTI‘s are that both circulating and clot 
bound thrombin can be theoretically inhibited.  
These are classified into naturally occurring compounds and synthetic compounds.  
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1.5.2.1 Naturally occurring compounds 
Hirudin was extracted from the salivary glands of the medicinal leech Hirudo 
medicinalis in 1957. It is a polypeptide having 60 residues and is the most potent DTI 
known till date having an Ki of ~20 fM. The primary sequence of hirudin has a sulfated 
Tyr
63
(Figure 11). The binding of hirudin to thrombin is a slow process involving many 
steps
63
. 
 Recombinant hirudins were made due to the high affinity of natural hirudin and differ at 
only the three residues in the carboxyl terminus from hirudin. These recombinant 
peptides (desiuridin, lepiuridin and bivaluridin) have Ki values of 60 fM, 200 fM and 1-2 
nM
64, 65
. These molecules are bivalent thrombin inhibitors binding to the exosite-I and the 
hydrophobic region near the active site. 
Triabin is also another natural peptide that inhibits thrombin
66
.Nazumamide A, 
A90720A are also natural products that have an arginine which recognize Asp
189
 in the 
S1 specificity pocket of thrombin
67, 68
. 
Theromin, a 67 amino acid peptide produced by the Rhynchobdellid leech, is the most 
potent inhibitor of thrombin described till date (Ki = 12 ± 5 fM). The molecule had no 
sequence homology with any other animal thrombin inhibitor characterized so far. It is 
suggested that dimerization is required to give the protein an active folded configuration 
that can bind to thrombin; however, the monomers are found to have inhibitory activity
69
. 
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Figure 11 The sequence of naturally occurring hirudin. Recombinant hirudins do 
not have a sulfate at Tyr
63
. The residues in red consist of the C-terminal exosite-1 
recognition sequence and the residues in blue recognize the active site. (Figure adapted 
from Rydel, T. J.; Ravichandran, K. G.; Tulinsky, A.; Bode, W.; Huber, R.; Roitsch, C.; 
Fenton, J. W.,2nd The structure of a complex of recombinant hirudin and human alpha-
thrombin. Science 1990, 249, 277-280. 
 
 
1.5.2.2 Synthetic compounds 
1.5.2.2.1 Irreversible Covalent Inhibitors 
The peptide chloromethyl ketone D-Phe-Pro-Arg-CH2Cl (PPACK, 1) is used as an 
affinity label for the active site of thrombin. It irreversibly acylates His
57
 of the catalytic 
triad and inhibits thrombin
70
. However these molecules show no selectivity over other 
serine proteases. 
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1.5.2.2.2 Reversible Covalent Inhibitors 
These class of molecules have an electrophillic moiety (serine trap), which is susceptible 
to attack by the active site serine forming a reversible hemiacetal. Several electrophillic 
groups which have been used are ketones, trifluoromethyl ketones, α-diketones, α-keto 
heterocycles, α-keto amides, α-keto esters, organoboronic acids and organophosphonic 
acids
71-73
. Some of the molecules under clinical evaluation are compound 2 (GYKI-
14766, Ki = 1.2 nM), compound 3 (CVS-1123), compound 4 (DUP-714, Ki = 40 pM)
74-
77
. 
However these compounds have a reactive functional group, which may make it less 
selective against other coagulation proteases, more prone to metabolism and more toxic. 
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1.5.2.2.3 Reversible Non – Covalent Inhibitors 
The lack of any serine trap is a characteristic of non covalent DTI‘s. This reduces a 
potential for toxicity and the molecule can bind to the enzyme subsites by electrostatic 
and hydrophobic interactions. Due to these reasons, several research groups have 
concentrated their work on this class of compounds
147
. 
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1.5.2.2.3.1 Guanidine or Amidine based molecules  
The first compounds developed, compound 6 (NAPAP, Ki = 6 nM), and compound 7 
(argatroban, Ki = 39 nM) were derived from the arginine derivative N-α-tosylarginine 
methyl ester (TAME, 5)
78-80
. All of the molecules in this class have a guanidine or 
arginine in its P1 position, which was based on the rationale to have binding interactions 
with Asp
189
 in the S1 pocket of the protease.  Argatroban was the first rationally designed 
DTI to reach the clinic, however it is not orally bioavailable due to the highly basic 
guanidine moiety. 
H
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The researchers at Astra Zeneca developed compound 8 (inogatran, Ki = 15 nM)
81
. 
Systematic modifications resulted in compound 9 (melagatran, Ki = 2 nM)
82, 83
. The 
benzamidino group of melagatran goes in the S1 pocket, while the azetidine and the 
cyclohexyl ring are buried in the S2 and S3 pockets. Due to the low oral bioavailability of 
melagatran, compound 10 (ximelagatran) was developed as a prodrug
84, 85
. Ximelagatran 
is transformed to melagatran by two intermediates, which involves hydrolysis of the ester 
and reduction of the amidoxime group. Due to the increased hydrophobicity of 
ximelagatran, it was found to be more orally available. Despite the high efficacy and 
bleeding profile of ximelagatran in clinical trials, FDA rejected its approval due to its off 
target hepatotoxicity. 
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Boehringer Ingelheim developed compound 11 (dabigatran etexilat), which is a prodrug 
of 12 (dabigatran, Ki = 4.5 nM)
86
. It is acted upon by esterases in vivo to generate 
dabigatran. It is based on a 1,2,5 trisubstituted benzimidazole core scaffold. The molecule 
is under advanced phases of clinical trials. In the Bistro I and II study dabigatran etexilat 
demonstrated an acceptable safety profile and satisfactory antithrombotic potential
87, 88
. 
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Compound 13 (UK 156,406, Ki = 0.46 nM) developed by Allen et al. was modified from 
the lead argatroban
89
. The molecule had a tetrahydroisoquinoline group at P3 and a 
carboxylic acid and a olefin residue in the piperidine moiety at P2. The changes resulted 
in good oral bioavailability and the drug is in clinical trials
89
. 
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The most potent synthetic inhibitor till date is compound 14 (LB-30812, Ki = 3 pM). 
However due to the basic amidine group at P1 position, it is only moderately 
bioavailable
90
. 
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The BMS group used a piperidine unit at P1 to obtain compound 15 (BMS-189090, Ki = 
3.6 nM), which is in preclinical development
91
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1.5.2.2.3.2 Non – amidine based molecules 
 
The realization that the lipohilicity of the S1 pocket can be utilized for designing 
inhibitors spurred an interest for compounds which have a lesser basic P1 group and 
thereby be more orally bioavailable. 
Compound 16 (SSR-182289A, Ki = 31 nM) is an extremely potent DTI whose lead was 
argatroban. The P1 unit was replaced from guanidine in argatroban to a 3-aminopyridine 
moiety and thereby the molecule is orally bioavailable. The compound is under phase-II 
clinical trials
92
. 
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Oh et al. designed the compound 17 (LB-30057, Ki =0.38 nM) which has a less basic 
benzamidrazone in its P1 position. Also, it was shown to be orally active in dog models
93
. 
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Kane et al. optimized the P1 position of argatroban utilizing the lipophilicity of the S1 
pocket which has an Ala
190
 in addition to an Asp
189
. A lipophilic group benzothiazole was 
used in the P1 position to obtain compound 18 (CGH 752, Ki = 0.026 nM)
94
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Sanderson et al. used 3-amino-2-pyridinone and 5-amino-6-pyridinone acetamide 
scaffolds with an amino pyridine in P1 to get compound 19 (Ki = 0.85 nM) with an 
improved pharmacokinetic profile
95
. 
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Replacement of the pyridinone core with a more stable 3-alkylaminopyrazinone biostere 
lead to compound 20 (L-375,378, Ki = 0.8 nM), which was further selected for clinical 
trials
96
. 
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1.6 Factor Xa Inhibitors 
1.6.1 Synthetic Direct Non Covalent fXa inhibitors 
Initially the first molecules identified were based on bisbenzamidines. The early 
molecules originated were from thrombin inhibitor programs. The presence of basic 
amidine groups on the P1 and the P4 positions of the scaffold made the compounds 
poorly bioavailable. The first bisbenzamidines, which were identified as potent molecules 
were compound 21 (DABE, Ki = 573 nM) and compound 22 (BABCH, Ki = 610 
nM)
116,117
. 
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Upon replacing one of the basic benzamidine/amidine moieties on the scaffold (either P1 
or P4) with a lesser basic functional group resulted in higher oral bioavailability. But this 
lowered the selectivity of the molecule towards fXa against other serine proteases. 
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However, when the remaining benzamidine/amidine was substituted with another lesser 
basic group highly potent, selective and orally bioavailable inhibitors were discovered.  
Compound 23 (rivaroxaban, Ki = 2.1 nM) is currently the most advanced inhibitor in 
clinical trials. In 2008, it was approved by the European commission for prevention of 
venous thromboembolism (VTE) after total knee and hip replacement. The cocrystal 
structure of with fXa (PDB code 2W26) shows that the oxazolidinone ring serves as the 
core to direct the morpholine residue into the S4 pocket and the chlorothiophene into the 
S1 pocket. Hydrogen bonds are seen between amide N-H of Gly
219
 and the carbonyl of 
the oxazolidinone and between the carbonyl of Gly
219
 and the N-H of the thiophene 
carboxamide
118-121
. In the S1 pocket the important interaction is between the chlorine and 
the aromatic ring of Try
228
.  
N
O
N
O
H
N
O
S
Cl
O
O
RIVAROXABAN
23  
 
Phenylglycinamide series of compounds with a rigid P4 unit and an indole in the P1 
position displayed Ki values in the lower nM range. Among the series, compound 24 
(LY-517717, Ki = 4.6 nM) showed 25% to 82% oral bioavailability and a 1000 fold 
selectivity against other serine proteases. The compound was advanced to phase-II 
clinical trials
122,123
.  
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Among a set of compounds with a pyrazole scaffold and benzamidine as the P1 
substituent, replacement of the P1 substituent with less basic or neutral scaffolds was 
explored. It was found that lowering the pKa of the P1 position systematically improved 
oral bioavailability. Substituting the P1 with a 3-aminobenzisoxazole moiety and 
optimizing the P4 with dimethylaminomethylimidazole gave the compound 25 
(razaxaban, Ki = 0.19 nM). The cocrystal structure of 25 with fXa shows that the 
aminobenzisoxazole binds to the S1 pocket and the amino group interacts with Asp
189
 
and the carbonyl of Gly
218
. The imidazole binds in the S4 pocket with a hydrogen bond to 
Glu
97
. The compound passed phase-II trials; however, it was withdrawn for undisclosed 
reasons
124,125
. 
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There were concerns about the pyrazole carboxamide core present in compound. It might 
hydrolyze in physiological conditions to release a potentially mutagenic biarylaniline. 
One of the approaches to this issue was to replace the nitrogen of the carboxamide 
scaffold with a methylene group. Further optimization lead to compound 26 (apixaban, 
Ki = 0.08 nM). The compound was found to be highly selective for fXa against thrombin 
and trypsin. The cocrystal structure of compound bound to fXa (PDB code 2PI6) showed 
that the p-methoxy group goes in the S1 pocket, the pyrazole interacts with Gln
192
 and the 
carboxamide carbonyl interacts with Gly
216
. The lactam is found in the S4 pocket 
interacting with Tyr
99
 and Phe
174
. This compound showed an oral bioavailability of 58% 
and has advanced to phase-III trials
126,127
.    
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In a set of amino acid derivatives of fXa inhibitors synthesized, a compound was reported 
to have a Ki of 9.4 nM. Removal of the phenyl group and SAR exploration around P4 
lead to the compound 27 (otamixaban, Ki = 0.4 nM). Moreover, the compound was found 
to be highly selective against other serine proteases. The cocrystal structure of compound 
27 bound to fXa (PDB code 1KSN) showed that the benzamidine is in the S1 pocket and 
the heterobiaryl group is in the P4 pocket. A hydrogen bond is found between the 
carbonyl of the amide and N-H of Gly
219
.  The compound was advanced to phase-II 
clinical trials
128,129
. 
  39 
O
O
N
H
O
N+
H2N NH
O-
OTAMIXABAN
27
 
In a series of pyrazoles, compound 28 (DPC-423, Ki = 0.15 nM) showed an improved 
pharmacokinetic profile compared to others in the series. It has a benzylamine in the P1 
position and a substituted phenyl group in the P4 position and a pyrazole carboxamide 
core. Compound 28 showed an oral bioavailability of 57%. The molecule was selective 
against other coagulation proteases however, not against trypsin and kallikrein. DPC-423 
is in phase-I clinical trials
130
. 
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Compound 29 (KFA-1411, Ki = 1.7 nM) has been found to be a highly potent and 
selective inhibitor of fXa. It has an amidine moiety both at the P1 and P4 positions. 
Compound 29 is under phase-I clinical trials
131
.  
Compound 30 (DX-9065a, Ki = 41 nM) is a naphthyl-amidine based fXa inhibitor, which 
inhibits free fXa, clot bound fXa, fXa in the prothrombinase complex and clot bound 
prothrombinase complex. The naphthyl-amidine moiety binds to the Asp
189
 in the S1 
pocket and the pyrrolidine goes to the S4 pocket. However it is not orally bioavailable 
and its prodrug DU-176b is in phase-II clinical trials
132
.    
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1.6.2 Limitations of Direct Inhibitors 
The hirudins are associated with major bleeding episodes, which limits their use in 
patients refractory to UFH
134, 135
. As hirudins are foreign peptides, they are potentially 
immunogenic and may cause life threatening disorders. Due to the high potency of 
hirudins for thrombin, there is no antidote for their use
49
. As a result bivalirudin was 
developed however, it has a shorter half life (25 min) because thrombin cleaves its Arg
3
-
Pro
4
 bond. Argatroban, approved for patients having a high risk for HIT, has a shorter 
half life and is associated with bleeding risks. Moreover, a significant limitation for the 
direct inhibitors is the presence of the highly basic guanidine or the arginine moiety 
which doesn‘t make them orally bioavailable. To counteract this problem ximelagatran 
was developed as a pro-drug of melagatran and was approved for clinical use in Europe. 
But US FDA rejected its application in 2004 due to concerns of hepatotoxicity
136
. Recent 
studies also show that inhibitors which use a basic group as the P1 moiety may cause 
degranulation of mast cells resulting in histamine release
136,137
. Therefore, a lot more 
challenges persist to develop a direct inhibitor which addresses all these issues.   
 
1.7 Rationale for the work 
With a goal of developing dual fXa and thrombin inhibitors, which can mimic heparins 
but are less polyanionic and more hydrophobic, our lab had designed sulfated 
dehydropolymers (DHP) from enzymatic coupling of 4-hydroxy cinnamic acids followed 
by the chemical sulfation of the free phenolic groups giving sulfated dehydropolymers. 
An example of such a molecule is CDSO3 (Figure 12). The average molecular weight of 
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CDSO3 was found to be 3320 and the range of oligomeric chain length varied from 5-13 
monomeric units. CDSO3 was found to contain an average of 0.4 sulfate groups per 
monomer
37
. 
Inhibition studies on thrombin and fXa in presence and absence of AT indicated that 
CDSO3 inhibited both the proteases preferentially by a direct mechanism, i.e. in the 
absence of AT with an IC50 value of 18 nM and 34 nM for thrombin and fXa, 
respectively. Michaelis – Menten kinetics indicated that Km was unaffected in the 
presence of these inhibitors, whereas Vmax decreased steadily. Thus, CDSO3 did not 
affect the formation of the Michaelis – Menten complex, while the forward rate constant 
of hydrolysis of the substrate (kcat or k2) is significantly reduced. These results suggest a 
non – competitive mechanism of enzyme inhibition, wherein the catalytic apparatus of 
the enzyme is disrupted by an allosteric mechanism
36
. Moreover, in whole blood and 
plasma coagulation assays (PT and APPT), CDSO3 displayed anticoagulation properties 
similar to the clinically used anticoagulant enoxaparin
138
. 
Being a polyanionic molecule, CDSO3 can theoretically bind either to the exosite-I or 
exosite-II of thrombin, both of which are known to bind anionic molecules. Competitive 
binding studies with exosite-I and exosite-II ligands indicate that CDSO3 binds in or near 
the anion binding exosite-II
36
. In a similar manner CDSO3 is expected to bind at the 
heparin binding exosite-II in fXa, as the exosite-I is cationic in character.  
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Figure 12 Preparation of CDSO3. The oxidative polymerization of caffeic acid by 
horseradish peroxidase and sulfation by triethyamine sulfur trioxide complex gives the 
heterogeneous CDSO3. The β-5 and β-O-4 linkages are highlighted. 
 
 
CDSO3 has been characterized as of having β-5, β-O-4, β-β and 5-5 inter-monomeric 
linkages where the β-5 and β-O-4 are predominant in its structure. In addition, CDSO3 is 
heterogeneous with variable numbers of sulfates, carboxylates, chiral centers and variable 
chain length. To study the role of these structural units require a large library of aromatic 
molecules with multiple sulfates, carboxylates and stereo-centers. Chemically, the 
structure of CDSO3 can be thought of as dihydrobenzofuran and phenoxypropanoic acid 
units, which could be successively, alternatively or randomly linked with each other. We 
hypothesized that delineation of key structural features of CDSO3 can be achieved by 
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accessing the importance of each contributing units, i.e., dihydrobenzofuran and 
phenoxypropanoic acid individually. Thus, we sought initially to synthesize a library of 
dihydrobenzofuran-like molecules and evaluate their inhibitory potential towards the two 
proteases – factor Xa and thrombin. 
The β-5 monomer of CDSO3 is a dihydrobenzofuran moiety with a carboxylate at 
position-3, sulfate at position-7 and two stereo-centers at C-2 and C-3. With a goal of 
simplifying the structure, we removed the chiral-centers and introduced aromaticity to 
arrive at a benzofuran  unit. Keeping an eye on the synthetic accessibility resulted in 5,6-
dihydroxy-benzofuran-3-carboxylic acid ethyl ester (1E, Figure 13). 
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Figure 13 The rationale behind synthesis of monomer 1E 
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 Monomer 1E served as the starting point to differentially introduce multiple sulfate and 
carboxylate groups on the benzofuran scaffold so as to study the structure-activity 
relationship (SAR) (Figure 14). The hydroxyl groups can be sulfated to their O-sulfates 
and the ethyl ester can be hydrolyzed to the corresponding carboxylic acid. In compounds 
where only one phenolic sulfate is present, the other hydroxyl group was sought to be 
protected as a methoxy group. Also we sought to study the effect of carbon homologation 
at the C-3 position, wherein the distance between the C-3 carboxylic acid and the ring 
was to be varied by one carbon. In this manner, a small focused library of compounds 
was designed.  
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Figure 14 The SAR sought to be explored around compound 1E 
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2 Synthesis and Biological Evaluation of β-5 like Monomers 
 
2.1  Synthesis of β-5 like monomers 
2.1.1 Synthesis of ethyl ester 1E 
The initial ethyl ester monomer 1E was synthesized by a laccase mediated oxidative 
coupling of catechol and ethyl-4-chloro acetoacetate in presence of the Lewis acid 
scandium triflate and SDS to solubilize the reactants in the aqueous buffer
139
. 43% yield of 
compound 1E was obtained, which is comparable to the literature yield of 46%. The 
compound was characterized by both 
1
H and 
13
C NMR, where in the characteristic two 
aromatic protons of 1E were distinguished. 
 
HO
HO
O O
OEt
Cl
O
HO
HO
O
O
CH3
Sodium phosphate buffer
Scandium triflate, laccase, SDS
1 2 1E
 
2.1.2 Synthesis of 1A 
The ethyl ester of 1E was sought to be hydrolyzed under traditional basic hydrolytic 
conditions in which either NaOH or LiOH in ethanol or methanol is used to expose the 
carboxylate group. However, these conditions gave a mixture of undesirable degradative 
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products as had been observed by 
1
H NMR (Table 1). It is possible that metal-catalyzed o-
quinol oxidation to the corresponding o-quinone, which might have further facilitated the 
benzofuran ring opening, resulting in degradation. 
OHO
HO
O
O
CH3
1E
OH-
Degradation products
 
 
Table 1 Reagents and conditions tried for synthesis of 1A 
Reagents and conditions Outcome 
NaOH/EtOH, 60
0
C Degradation 
NaOH/EtOH, 0
0
C Degradation 
LiOH/MeOH, 0
0
C Degradation 
Na t-BuO, H2O, DMSO Degradation 
 
Then an alternative synthetic plan was devised. The catechol was protected with 
dichlorodiphenylmethane followed by hydrolysis of the ethyl ester under basic hydrolytic 
conditions in one pot and isolation of the protected acid 8 in 63% overall yield. 
1
H NMR 
indicated the presence of the carboxylic acid proton at 12.97 δ and twelve aromatic protons 
in 7.36-7.56 δ suggesting the formation of 8. Then, under aqueous acidic conditions, which 
is described in literature for the removal of the diphenylmethane protecting group, the 
compound 1A was isolated in 69% yield. 
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O
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O
CH3
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Ph
O
O
O
O
OH
CH3
Ph
Ph
NaOH
EtOH, 800C
1E 8
1800C
AcOH/H2O
Reflux
O
HO
HO
O
OH
CH3
1A  
2.1.3 Synthesis of 6ES 
6ES was synthesized by a microwave based sulfation protocol developed in our lab that 
uses trimethylamine sulfur trioxide complex and triethylamine base in acetonitrile under 
microwave, followed by purification using size-exclusion chromatography
140
. The 
trialkylamine salt of the sulfate was exchanged to the sodium salt using cation-exchange 
columns to give the corresponding sulfate 6ES in 90% yield. Characterization was 
performed by using 
1
H NMR wherein a characteristic downfield shift of the aromatic 
protons is observed when two sulfates are introduced in the product. These protons are 
seen at 7.42-7.73 δ, whereas they resonate at 6.95-7.37 δ in the un-sulfated precursor 1E.  
O
HO
HO
O
O
CH3 Me3NSO3, Et3N
MeCN, 50 W, 100 C
O
O
O
O
O
CH3
NaO3S
NaO3S
1E 6ES  
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2.1.4 Synthesis of 6AS 
Conversion of the ester into the corresponding acid worked with the anhydrous ester 
hydrolysis protocol previously used in our lab for compounds with sulfates. The method 
uses potassium t-butoxide in anhydrous DMSO having one equivalent of H2O to hydrolyze 
the ester, followed by size-exclusion chromatography to purify the compound
141
. 
Traditional hydrolytic conditions like NaOH in ethanol and HCl in ethanol resulted in the 
breakdown of the sulfate groups. Compound 6AS was obtained in 90% yield and was 
characterized by 
1
H and 
13
C NMR, which showed the absence of an ester group, and mass 
spectrometry, which indicates the parent ion peak. 
 
 
O
O
O
O
O
CH3
NaO3S
NaO3S
K-tBuO, H2O
DMSO
O
O
O
O
ONa
CH3
NaO3S
NaO3S
6ES 6AS  
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2.1.5 Synthesis of sulfates 4ES and 5ES 
To protect either one of the phenolic groups as a methoxy group, the ethyl ester monomer 
1E was treated with methyl iodide and cesium carbonate in DMF to give the regioisomers 
2E and 3E in 53% and 30% yield respectively. 
O
HO
HO
O
O
CH3
MeI, Cs2CO3
DMF
O
O
HO
O
O
CH3
O
HO
O
O
O
CH3
1E 2E 3E  
According to literature, the regioisomer 2E would be the product in the highest yield due 
to the increased acidity of the 6-hydroxy group when compared with the 5-hydroxy group. 
Interestingly, the Rf values of the regioisomers were different on silica, hence they could 
be purified using flash chromatography on silica. 
1
H and 
13
C spectra for the compounds 
indicated an obvious difference in the ppm values of the isomers. A NOESY experiment, 
which correlates proton-proton through space coupling, was used to confirm the structure 
of 2E. The 
1
H NMR spectrum of 2E shows peaks at 7.44, 6.95, 5.58, 4.48, 3.96, 2.75 and 
1.46 δ. The NOESY spectrum shows cross-peaks between 7.44 and 1.46 δ protons, 
suggesting that the aromatic proton ‗a‘ is in close proximity to ester –CH3- ‗g‘ (Figure 15). 
This correlation was used to assign the aromatic resonances and confirm the compound 
2E. 
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   Figure 15 
1
H assignments and
 
NOESY correlation for compound 2E   
 
O
CH3
O
O
O
CH3
HO
H
H
a
b
c
e
f
d g2E  
Protons 
1H (δ) 1H – 1H correlations 
a 7.44 (s) a-g 
b 6.95 (s) b-e 
c 5.58 (s) c-a, c-e 
d 4.39 (q) d-g 
e 3.96 (s) e-b, e-a, e-c 
f 2.75 (s) f-g 
g 1.46 (t) g-f, g-d, g-a 
 
Sulfates were introduced onto the free phenolic groups of 2E and 3E using the base-
catalyzed, microwave- assisted protocol described earlier to give 4ES and 5ES in yields of 
94% and 92%, respectively. 
1
H NMR was used to confirm the compounds in which a shift 
of one of the aromatic protons that is adjacent to the introduced sulfate group is observed 
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(7.97 δ in 4ES when compared to 7.44 δ in 2E and 7.13 δ in 5ES when compared to 7.40 δ 
in 3E). 
 
O
RO
R'O
O
O
CH3
Me3N:SO3, Et3N
MeCN
2E: R=Me, R'=H
3E: R=H, R'=Me
O
RO
R'O
O
O
CH3
4ES: R=Me, R'=SO3
-Na+
5ES: R=SO3
-Na+, R'=Me  
 
2.1.6 Synthesis of 4AS and 5AS 
The ethyl esters of 4ES and 5ES were hydrolyzed using the anhydrous ester hydrolysis 
protocol using potassium t-butoxide in DMSO. Compounds 4AS and 5AS were isolated in 
yields of 90% each and were confirmed by 
1
H, 
13
C NMR and mass spectroscopy. The 
absence of the ester protons and carbons in the 
1
H and 
13
C NMR was used to confirm the 
compounds. Moreover, mass spectrometry indicated the parent ion peak of these 
compounds. 
O
RO
R'O
O
O
CH3
O
RO
R'O
O
O-Na+
CH3
4AS: R=Me, R'=SO3
-Na+
5AS: R=SO3
-Na+, R'=Me
4ES: R=Me, R'=SO3
-Na+
5ES: R=SO3
-Na+, R'=Me
Kt-BuO, H2O
DMSO
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2.1.7 Synthesis of 2A 
The hydrolysis of the ethyl ester in compound 2E occurred uneventfully under basic 
hydrolytic conditions to give compound 2A in 90% yield. The compound was confirmed 
by 
1
H and 
13
C NMR wherein the ester protons and carbons were absent. Also, mass 
spectrometry indicated the parent ion peak of the product 2A. 
O
O
HO
O
O
CH3
NaOH
EtOH, 800C
O
O
HO
O
OH
CH3
2E 2A  
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2.1.8 Synthesis of 1XS 
To make compound 1XS, a synthetic plan was devised in which the ethyl ester in 2E was 
reduced to an alcohol by a hydride delivering agent and then sulfates are introduced on 
both of the hydroxyl groups. The compound 1X was isolated on reduction of 1E with LAH 
in a yield of 84%. The structure of 1X was confirmed by 
1
H and 
13
C NMR wherein the 
characteristic benzylic  protons  at 4.65 δ are observed.   
O
O
HO
O
O
CH3
LiAlH4
THF
O
O
HO
OH
CH3
2E 1X  
 
However, sulfation of 1X to obtain 1XS did not succeed as 1XS was found to be unstable 
in aqueous solution.  The reason for this unstability is unclear at this time. 
  
 
O
O
HO
OH
CH3
1X
Me3N:SO3, Et3N
MeCN
O
O
+Na-O3SO
OSO3
-Na+
CH3
1XS  
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2.1.9 Synthesis of 8ES and 8AS 
To study the effect of homologation by an additional carbon at the C-3 position, a  
synthetic strategy was envisioned such that disconnection of the CH2-COOH bond of the 
target 8AS by the Wittig reaction leads to the benzofuran-3-aldehyde precursor 12 and 
methoxymethylene triphenylphosphorane (MMTPP). The synthesis of 12 would 
commence from the compound 2E by reduction of the ester to the aldehyde 12 by a 
sterically hindered hydride delivery agent, followed by protection of the phenolic group 
and Wittig with MMTPP to give the compound 11. The acidic hydrolysis of the Witting 
derivative to give the aldehyde, followed by sulfation of the free phenolic group and 
oxidation of the aldehyde to the corresponding carboxylic acid would lead to 8ES and 8AS 
(Figure 16).     
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Figure 16 Reterosynthetic analysis and scheme for 8ES and 8AS  
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The reduction of the compound 2E to the aldehyde derivative 10 proved to be problematic 
as no reaction occurred with the common hydride reducing agent DIBAL. Hence for 
synthesizing compound 10, one more step was added in the sequence: reduction of the 
ester to the alcohol with LAH and oxidation of the alcohol to the aldehyde. The protection 
of the phenol to a silyl derivative was carried out before the reduction because of ease of 
handling the now protected derivative 9 (Figure 17). 
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Figure 17 Strategy for synthesis of 10 from compound 2E 
O
O
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CO2Et
CH3
2E
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1) TBDMS protection
O
O
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CH3
(O)
O
O
TBDMSO
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CH3
9 10
 
The compound 2E was converted into the silyl derivative and the ester was reduced into 
the alcohol 9 using LAH. Compound 9 was obtained in 80% yield and confirmed by 
1
H 
NMR, which shows the presence of the -CH2- protons at 4.69 δ. However, the oxidation of 
compound 9 to the aldehyde 10 proved to be difficult with common mild oxidants like 
chromate salts and Dess Martin periodinane, giving unsatisfactory yields. Experiments 
with TEMPO (2,2,6,6-Tetramethylpiperidine-1-oxyl
 
)
142
 gave satisfactory yields to give the 
compound 10 (Table 2), which was characterized by 
1
H NMR. The characteristic aldehyde 
proton at 10.15 δ and the absence of the –CH2- protons observed in 9 were used to confirm 
the product 10.  
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Table 2 Optimization of Oxidation Conditions  
Reagent Yield 
MnO2 No conversion 
PCC, DCM, rt 10% 
PCC, DCM, μw 17% 
DMP, DCM 40% 
TEMPO, NCS, DCM 80% 
 
The Wittig reaction proceeded with the aldehyde to obtain a compound 11 that was a 
mixture of both isomers. However the the acidic hydrolysis of 11 resulted in degradation. 
 
2.1.10 Synthesis of 7ES 
Due to the degradation of the Wittig derivative 11, an alternative approach was devised in 
which, instead of a one carbon homologation, a two carbon increase in the linkage between 
the ester and the aromatic scaffold was devised to give the new target 7ES. Again 
disconnection of the target 7ES at the CH2-CH2 bond by Wittig and subsequent 
hydrogenation of the olefin gives compound 10 and (carbethoxy) methylenetriphenyl 
phosphorane (CEMTPP) (Figure 18). 
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Figure 18 Retrosynthetic analysis of 7ES 
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Then, from compound 10, the scheme described above could be followed. The Wittig 
reaction occurred and the trans isomer was isolated from the reaction mixture in 96% yield. 
The double bond was reduced by hydrogen over palladium to give the crude 12. 
1
H NMR 
of the crude 12 indicated a mixture, which suggested that partial de-silylation had 
occurred. The silyl group was subsequently removed using TBAF to give the compound 
7E. The structure of 7E was determined by 
1
H NMR, wherein the four protons of -CH2-
CH2- were distinctly observed at 2.59 and 2.87 δ. The ester protons were also distinguished 
at 1.22 and 4.12 δ. Following, microwave-based sulfation gave the compound 7ES in 39% 
yield and was confirmed by 
1
H NMR wherein the downshifted aromatic proton which 
resonated at 7.50 δ when compared to 6.94 δ for the unsulfated precursor 7E. 
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2.1.11 Synthesis of 7AS 
The ethyl ester present in 7ES was subsequently hydrolyzed by the anhydrous ester 
hydrolysis protocol to give the compound 7AS in 91% yield. The compound was 
confirmed by 
1
H NMR, wherein the absence of the ester protons confirmed the presence of 
7AS. Moreover, mass spectrometry indicated the parent ion peak of 7AS.  
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2.1.12  Synthesis of 7A 
Under basic hydrolytic conditions the ethyl ester present in compound 7E was hydrolyzed 
to compound 7A in 50% yield. The structure of 7A was confirmed by 
1
H, 
13
C NMR and 
mass spectrometry. 
O
O
HO
CH3
7E
CO2Et
NaOH, EtOH
80oC
O
O
HO
CH3
7A
CO2H
 
 
2.2  Direct inhibition of thrombin and factor Xa (Work performed by Dr. Liang) 
To determine whether the β-5-like monomers synthesized inhibit the coagulation proteases 
– fXa and thrombin, the residual enzymatic activity of the proteases was measured by 
following spectrophotometrically the initial rate of hydrolysis of the appropriate 
chromogenic substrate. Spectrozyme TH and S-2772 were used as substrates for thrombin 
and fXa. Relative residual protease activity (in %) at each concentration of the β-5 like 
monomer was calculated as a ratio of the slopes measured in the presence of the inhibitor 
to that in its absence
37
. From the residual protease activity, the percentage of the enzyme 
inhibited was determined. 
 Out of the seventeen molecules screened, only seven of them (1A, 2A, 4AS, 5AS, 6AS, 
7A and 7AS) exhibited any inhibition potential (Figure 19). The minimal concentration of 
these compounds necessary to display inhibition was approximately 400 μM. All the other 
derivatives in the library were found to be inactive below 4.3 mM.   
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Figure 19 Inhibition of Thrombin (upper plot) and Factor Xa (lower plot) by the 
β-5 like monomers 1A, 2A, 4AS, 5AS, 6AS, 7A and 7AS. The compounds were present 
at 2.9 mM (thrombin) or 2.6 mM (fXa), except for the asterisk (*) labeled cases where 
concentration was 4.3 mM. The standard error in the experiments was less than 10%. 
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2.3 Mechanism of Factor Xa Inhibition (Work performed by Dr. Liang) 
To determine the mechanism of inhibition of factor Xa by the synthesized β-5-like 
monomers, the kinetics of S-2772 hydrolysis by factor Xa in the presence and the absence 
of the compound 5AS were determined. The initial rate of hydrolysis varied in a 
hyperbolic manner with the concentration of the substrate from which the Michaelis 
constant (KM) and maximal velocity of the reaction (VMAX) were derived (Figure 20). The 
KM and VMAX for S-2772 in the absence of compound 5AS was found to be 441±86 μM 
and 197±22 mAUmin
-1μM-1 respectively. In the presence of 5AS the values changed to 
61±13 μM and 54±4 mAUmin-1μM-1 respectively. 
 
Figure 20 Hydrolysis of substrate S-2772 by factor Xa in the presence () and 
absence () of 2.6 mM 5AS. The solid lines represent the fits to Michaelis – Menten 
equation to derive KM and VMAX values 
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2.4  Discussion 
Of the seventeen β-5 like monomers made, only 1A, 2A, 4AS, 5AS, 6AS, 7A and 7AS 
displayed inhibitory properties.  This indicates that only selected monomeric units with 
appropriate substitutions carry the property of direct inhibition of thrombin and factor Xa. 
The minimal concentration required to display inhibition was 400 μM, which is fairly high. 
However interesting structure-activity relationships could be deduced from the study.  
All ester containing monomers exhibited no inhibition, suggesting an important role for the 
–COO- group. Whereas no molecule displayed more than 40% inhibition of thrombin at 
2.9 mM, at least four out of seven (4AS, 5AS, 6AS and 7A) inhibit factor Xa better 
(>40%) at 2.6 mM. This suggests a slight preference of the benzofuran scaffold for 
inhibition of factor Xa.  
Importantly, inhibitors 5AS and 6AS display 86% and 75% inhibition of factor Xa 
respectively, which is better than all the other inhibitors. This suggests a significant 
selectivity of recognition of these molecules by the enzyme. The common pharmacophore 
present in these two molecules is the 3-COO
-
 and the 6-OSO3
-
 unit, which is absent in all 
the other molecules. Interestingly, the molecule 4AS, which is the regioisomer of 5AS, 
only inhibits factor Xa 42%, when compared to 5AS (86%), supporting a preferential 
recognition hypothesis. 5AS and 6AS more closely resemble the native CDSO3 dihydro-
benzofuran monomer than molecules 7A and 7AS, which have a non-native extended 
COO
-
 bearing linker. 
The decrease of the KM value from 441±86 μM to 61±13 μM and the VMAX from 197±22 
mAUmin
-1μM-1 to 54±4 mAUmin-1μM-1 for the hydrolysis of S-2772 by factor Xa in 
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presence of 5AS indicate that in presence of the inhibitor the binding of the substrate to the 
active site of the protease is significantly affected. Specifically the interaction of 5AS with 
factor Xa results in a 7-fold increase in affinity of the substrate towards the enzyme and a 
3.6 fold decrease in the catalytic rate of hydrolysis. Thereby, the presence of 5AS 
introduces structural changes in the active site of factor Xa that alters the formation of the 
factor Xa-S-2772 Michaelis complex as well as induces dysfunction of the catalytic 
apparatus of the enzyme. Considering that the lead, i.e., CDSO3, binds to the exosite-II of 
thrombin, these results support the hypothesis that these β-5-like monomers also inhibit 
thrombin and factor Xa through exosite-II mediated allosteric dysfunction of the catalytic 
triad. 
 
2.5 Experimental section 
2.5.1 General methods 
Reagents/chemicals were purchased from Sigma-Aldrich (unless specified otherwise) and 
used as supplied. Analytical thin layer chromatography (TLC) was performed using 
UNIPLATE
TM
 silica gel GHLF 250 μm pre-coated plates (ANALTECH, Newark, DE) 
with a fluorescence indicator (254 nm). Column chromatography was performed using 
silica gel (60 A
o
, 200-400 mesh, Sigma-Aldrich). Microwave-assisted sulfation reactions 
were performed using CEM-Discover (Matthews, NC) synthesizer in sealed reaction 
vessels (7 ml). The reaction condition was set to ramp to 100
o
C at 50 W and was 
maintained by cooling with nitrogen at 45 psi. 
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Sephadex G10 chromatography and SP Sephadex-Na chromatography (cation exchange) 
were performed using flex columns (KIMBLE/KONTES, Vineland, NJ) of dimensions 
170 × 1.5 cm and 75 × 1.5 cm. Cation exchange was  performed using 30 fold excess of 
sodium ion equivalents. Samples were chromatographed at a controlled flow rate of 0.5 
ml/min using water or 20% EtOH/H2O as the eluent. Fractions of 5 mL each were 
collected and analyzed by RP-HPLC or capillary electrophoresis. 
HPLC analysis was carried out on a Shimadzu chromatography system using Waters 
Atlantis dC18 column (5 µm, 4.6 × 250mm). The mobile phase consisted of acetonitrile – 
water mixture (2:8 v/v) run at a flow rate of 0.5 ml/min. Analysis was carried out using a 
UV-VIS detector at 254 nm. 
Capillary electrophoresis was performed using a P/ACE MDQ
TM
 Beckman capillary 
electrophoresis system (Fullerton, CA). The experiments were performed at a constant 
voltage of 8 kV and constant pressure of 0.1 psi. An uncoated fused silica capillary (I.D. 
75 mm) of 31.2 cm total length with a 5 mm detection window at 21.0 cm length from the 
injection point was used. During electrophoresis, the capillary was held at a constant 
temperature of 25 °C. Sequential washes of 1 M HCl for 10 min, high purity water for 3 
min, 1 M NaOH for 10 min and high purity water for 3 min at 20 psi were used to activate 
a new capillary. Before each electrophoretic run, the capillary was rinsed with the run 
buffer for 3 min at 20 psi. Run electrolytes containing 50 mM sodium phosphate buffer, 
pH 3.0. Sample solution in deionized water was injected at the cathodic end using 0.5 psi 
pressure for 5 s. Electrophoresis was monitored at the anodic end by following absorbance 
at 254 nm. 
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1
H NMR and 
13
C NMR were recorded on Varian Mercury-300 MHz spectrometer in 
CDCl3, DMSO-d6, CD3OD, acetone-d6, or D2O. All signals are reported in ppm with the 
residual chloroform, DMSO, acetone, and H2O signals at 7.26, 2.50, 3.31, 2.05, and 4.79, 
respectively, as standards. The data is reported as: chemical shifts (ppm), multiplicity (s = 
singlet, d = doublet, t = triplet, m = multiplet), coupling constant(s) (Hz), and integration. 
ESI mass spectra were recorded using a Micromass ZMD 4000 single quadrupole 
spectrometer. Samples were dissolved in 5% formic acid in methanol and infused at a rate 
of 10 μL/min. Mass scans were obtained in the range of 100-900 amu at a scan rate of 400 
amu/s. Ionization conditions were optimized for each compound to maximize ionization of 
the parent ion. The capillary voltage was varied between 3.0 and 5.0 V, while the cone 
voltage ranged from 20 to 85 V. For all experiments the extractor voltage was set to 3.0, 
the Rf lens voltage to 0.1 V, the source block temperature to 100
0
C and the desolvation 
temperature to 150
0
C. 
Proteins —Human coagulation factors Xa and IIa (-thrombin) were purchased from 
Haematologic Technologies (Essex Junction, VT). Stock solutions of proteins were 
prepared in 20 mM sodium phosphate buffer, pH 7.4, containing 100 mM NaCl and 2.5 
mM CaCl2 (AT and thrombin) or 5 mM MES buffer, pH 6.0 (factor Xa). Chromogenic 
substrates Spectrozyme TH was purchased from American Diagnostica (Greenwich, CT), 
while substrate Chromogenix S-2772 was from DiaPharma group, Inc (West Chester, 
Ohio). 
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2.5.2 Synthesis of 1E 
To a solution of catechol 1 (550 mg, 5 mmol, 1.0 equiv) in sodium phosphate buffer (150 
ml, 0.1 M, pH 7) were added laccase (25 mg, 500 U), chloro ethyl acetoacetate 2 (Alfa 
Aesar) (1.385 ml, 10 mmol, 2.0 equiv), scandium triflate (492 mg, 1 mmol, 0.2 equiv), and 
sodium dodecyl sulfate (Fischer Biotech) (288.38 mg, 1 mmol, 0.2 equiv). The reaction 
mixture was vigorously stirred. After 4 hours the reaction mixture was acidified to pH 2 
using HCl and filtered on celite. The residue was dissolved in ethyl acetate, dried using an. 
Na2SO4 and concentrated to a powder, which was purified by flash chromatography on 
silica gel (30% EtOAc in hexanes) to give 1E (510 mg, 2.16 mmol, 43%). 
1
H NMR 
(acetone-d6, 300 MHz) δ 1.36 (t, J =3 Hz, 3H, CH3), 2.63 (s, 3H, CH3), 4.31 (q, J =6 Hz, 
2H, CH2), 6.95 (s, 1H, Ar-H), 7.37 (s, 1H, Ar-H), 7.99 (s, 2H, OH) (Figure 21). 
13
C NMR 
(CDCl3) δ 14.79, 14.96, 60.54, 98.53, 106.62, 108.83, 117.56, 144.09, 144.92, 147.79, 
161.79, 164.48 (Figure 22). 
2.5.3 Synthesis of 1A 
To 1E (100 mg, 0.423 mmol, 1.0 equiv) in a two necked flask fitted with a reflux 
condenser was added dichlorodiphenyl methane (0.08 ml, 0.423 mmol, 1.0 equiv) under 
nitrogen. The reaction mixture was heated to 180
0
C. After 30 minutes the reaction mixture 
was allowed to cool to room temperature and ethanol (4.0 ml) and sodium hydroxide (0.8 
ml from 2N soln) were added, and the mixture was heated to 80
0
C. After 16 hours the 
reaction mixture was allowed to cool to room temperature and quenched with 2N HCl and 
extracted with ether and ethyl acetate. The organics were dried (Na2SO4), concentrated and 
purified using flash chromatography on silica gel (20-90% EtOAc in hexanes) to give 8 
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(100 mg, 0.27 mmol, 63%). 
1
H
 
NMR (DMSO-d6, 300 MHz) δ 2.63 (s, 3H, CH3), 7.36-7.56 
(m, 12H), 12.97 (s, 1H, OH) (Figure 23). 
To 8 (78.0 mg, 0.209 mmol, 1.0 equiv) in a two-necked flask fitted with a reflux condenser 
was added 80% AcOH/H2O (3 ml) and the mixture was refluxed. After 16 hours the 
mixture was cooled to room temperature and extracted with water and ethyl acetate. The 
organic extract was dried (Na2SO4), concentrated in vacuo and purified using flash 
chromatography on silica gel (10-60% EtOAc in hexanes) to give 1A (30 mg, 0.144 mmol, 
69%). 
1
H NMR (acetone-d6, 300 MHz) δ 2.67 (s, 3H, CH3), 6.97 (s, 1H, Ar-H), 7.41 (s, 1H, 
Ar-H) (Figure 24). 
13
C NMR 13.63, 97.64, 106.38, 108.91, 118.62, 143.11, 144.11, 
148.17, 161.89, 164.93 (Figure 25). ESI (-ve) m/z calcd for C10H8O5 [(M-H)
-
)] 207.04, 
found 206.88 (Figure 26). Capillary electropherogram (Figure 57B)  
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Figure 21  
1
H NMR of compound 1E 
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Figure 22 
13
C NMR of compound 1E 
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Figure 23  
1
H NMR of compound 8 
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Figure 24  
1
H NMR of compound 1A 
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Figure 25 
13
C NMR of compound 1A 
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Figure 26 ESI mass spectra for 1A 
OHO
HO
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H
O
OH
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2.5.4 Synthesis of 6ES 
To a solution of 1E (30 mg, 0.127 mmol, 1.0 equiv) in acetonitrile (0.8 ml) in a microwave 
tube were added triethylamine (0.31 ml, 2.286 mmol, 18.0 equiv) and trimethylamine-
sulfur trioxide complex (282.5 mg, 2.03 mmol, 16.0 equiv) under nitrogen. The mixture 
was exposed to microwaves (50 W, 30 min, 100
0
C). The process was repeated, the 
resulting mixture was concentrated in vacuo and 2 ml of water was added with stirring. 
The mixture was loaded onto a Sephadex G-10 column and was chromatographed with 
20% EtOH-water as eluent. Fractions were monitored using reverse phase HPLC, pooled 
according to similarity of migration profiles, concentrated and reloaded onto a SP 
Sephadex C-25 column. Appropriate fractions were pooled and lyophilized to give 6ES 
(101 mg, 0.23 mmol, 90%). 
1
H NMR (D2O, 300 MHz) δ 1.23 (t, J =6 Hz, 3H, CH3), 2.34 
(s, 3H, CH3), 4.13 (q, J =9 Hz, 2H, CH2), 7.42 (s, 1H, Ar-H), 7.73 (s, 1H, Ar-H) (Figure 
27). 
 
2.5.5 Synthesis of 6AS 
6ES (50 mg, 0.114 mmol, 1.0 equiv) was dissolved in DMSO (1.1 ml). To this solution 
were added potassium tert-butoxide (TCI AMERICA) (38.4 mg, 0.342 mmol, 3.0 equiv) 
and H2O (3.1 μl, 0.171 mmol, 1.5 equiv) under N2. The reaction was monitored on reverse 
phase HPLC and after 3 hours dibasic sodium phosphate (161.8 mg, 1.14 mmol, 10.0 
equiv) was added and stirred for an additional 30 minutes. The reaction mixture was 
loaded onto a Sephadex G-10 column and eluted with deionized water. The fractions 
containing the product were identified using a reverse phase HPLC, lyophilized to obtain 
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6AS (44.51 mg, 0.10 mmol, 90%). 
1
H
 
NMR (D2O, 300 MHz) δ 7.46 (s, 1H, Ar-H), 7.77 (s, 
1H, Ar-H), 2.54 (s, 3H, CH3) (Figure 28). 
13
C NMR 13.56, 105.84, 114.05, 114.87, 
125.63, 139.94, 140.16, 150.13, 162.27, 172.10 (Figure 29). ESI (+ve) m/z calcd for 
C10H5Na3O11S2 [(M+H)
+
)] 435.24, found 435.20 (Figure 30). Capillary electropherogram 
(Figure 57A). 
 
2.5.6 Synthesis of 4ES and 5ES 
To a solution of 1E (340 mg, 1.44 mmol, 1.0 equiv) in DMF (12 ml) were added cesium 
carbonate (234 mg, 0.72 mmol, 0.5 equiv) and methyl iodide (0.45 ml, 7.20 mmol, 5.0 
equiv) under N2. The reaction mixture was stirred for 15 hours, was quenched with 2N HCl 
and extracted into EtOAc. The organic extract was dried using an. Na2SO4, evaporated and 
the residue purified on silica gel (10-25% EtOAc in hexanes) to give 2E (192 mg, 0.77 
mmol, 53%) and 3E (108 mg, 0.43 mmol, 30%). 2E; 
1
H NMR (CDCl3, 300 MHz) δ 1.46 
(t, J=6Hz, 3H, CH3), 2.75 (s, 3H, CH3), 3.96 (s, 3H, CH3), 4.39 (q, J =6 Hz,, 2H, CH2), 
5.58 (s, 1H, OH) 6.95 (s, 1H, Ar-H), 7.44 (s, 1H, Ar-H) (Figure 31) . ESI (+ve) m/z calcd 
for C13H14O5 [(M+H)
+
)] 251.25, found 251.17;  3E; 
1
H
 
NMR (CDCl3, 300 MHz) δ 1.42 (t, 
J=6 Hz, 3H, CH3), 2.69 (s, 3H, CH3), 3.94 (s, 3H, CH3), 4.40 (q, J =9 Hz, 2H, CH2), 5.83 
(s, 1H, OH), 7.00 (s, 1H, Ar-H), 7.40 (s, 1H, Ar-H) (Figure 32), NOESY for 2E (Figure 
33). 
 
To a solution of 2E (34 mg, 0.136 mmol, 1.0 equiv) in acetonitrile (0.45 ml) in a 
microwave tube were added triethylamine (0.18 ml, 1.3 mmol, 10 equiv) and 
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trimethylamine-sulfur trioxide complex (151.4 mg, 1.08 mmol, 8.0 equiv) under nitrogen. 
The reaction mixture was exposed to microwaves (50 W, 30 min, 100
0
C). The mixture was 
concentrated in vacuo and purified by flash chromatography on silica gel (0-20% MeOH in 
DCM) and dried to give the triethylamine-sulfate salt. This was dissolved in 20% EtOH-
water and loaded onto a Sephadex C-25 column. Appropriate fractions were pooled and 
lyophilized to give 4ES (45 mg, 0.13 mmol, 94%). 
1
H
 
NMR (DMSO d6, 300 MHz) δ 1.35 
(t, J = 6 Hz, 3H, CH3), 2.52 (s, 3H, CH3), 3.78 (s, 3H, CH3), 4.32 (q, J = 6 Hz, 2H, CH2), 
7.25 (s, 1H, Ar-H), 7.97 (s, 1H, Ar-H) (Figure 34). 
To a solution of 3E (50 mg, 0.2 mmol, 1.0 equiv) in acetonitrile (0.7 ml) in a microwave 
tube were added triethylamine (0.27 ml, 2.0 mmol, 10 equiv) and trimethylamine-sulfur 
trioxide complex (222.6 mg, 1.6 mmol, 8.0 equiv) under nitrogen. The reaction mixture 
was exposed to microwave energy (50 W, 30 min, 100
0
C). The mixture was concentrated 
in vacuo and purified by flash chromatography on silica gel (0-20% MeOH in CH2Cl2) and 
dried to give the triethylamine-sulfate salt. This was dissolved in 20% EtOH-water and 
loaded onto a Sephadex C-25 column. Appropriate fractions were pooled and lyophilized 
to give 5ES (65 mg, 0.18 mmol, 92%).
 1
H
 
NMR (D2O, 300 MHz) δ 1.13 (t, J = 6 Hz, 3H, 
CH3), 2.18 (s, 3H, CH3), 3.56 (s, 3H, CH3), 3.94 (q, J = 9 Hz, 2H, CH2), 6.63 (s, 1H, Ar-
H), 7.13 (s, 1H, Ar-H) (Figure 35). 
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Figure 27 
1
H NMR of 6ES 
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Figure 28  
1
H NMR of 6AS 
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Figure 29  
13
C NMR of 6AS 
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Figure 30 ESI mass spectra of 6AS 
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Figure 31  
1
H NMR of 2E 
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Figure 32  
1
H NMR of 3E 
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Figure 33  NOESY for 2E with distinctive correlation’s in yellow 
 
  88 
Figure 34  
1
H NMR of 4ES 
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Figure 35  
1
H NMR of 5ES 
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2.5.7 Synthesis of 4AS and 5AS 
4ES (45 mg, 0.123 mmol, 1.0 equiv) was dissolved in DMSO (1.3 ml). To this solution 
were added potassium tert-butoxide (TCI AMERICA) (45.1 mg, 0.369 mmol, 3.0 equiv) 
and H2O (3.3 ml, 0.184 mmol, 1.5 equiv) under nitrogen. The reaction was monitored on 
reverse phase HPLC and after 3 hours dibasic sodium phosphate (174.6 mg, 1.23 mmol, 
10.0 equiv) was added and stirred for an additional 30 minutes. The reaction mixture was 
loaded onto a Sephadex G-10 column and eluted with deionized water. The fractions with 
the product were identified using reverse phase HPLC and lyophilized to obtain 4AS (38.3 
mg, 0.11 mmol, 90%). 
1
H
 
NMR (D2O, 300 MHz) δ 2.45 (s, 3H, CH3), 3.73 (s, 3H, CH3), 
7.04 (s, 1H, Ar-H), 7.61 (s, 1H, Ar-H) (Figure 36). 
13
C NMR 13.37, 56.44, 96.32, 113.81, 
114.75, 120.20, 137.10, 149.21, 151.28, 160.18, 172.46 (Figure 37). ESI (+ve) m/z calcd 
for C11H8Na2O8S [(M+H)
+
)] 346.97, found 347.15 (Figure 38). Capillary 
electropherogram (Figure 57A) 
5ES (73 mg, 0.199 mmol, 1.0 equiv) was dissolved in DMSO (2.0 ml). To this solution 
were added potassium tert-butoxide (TCI AMERICA) (73 mg, 0.598 mmol, 3.0 equiv) and 
H2O (5.3 μl, 0.298 mmol, 1.5 equiv) under nitrogen. The reaction was monitored on 
reverse phase HPLC and after 3 hours dibasic sodium phosphate (282.5 mg, 1.99 mmol, 
10.0 equiv) was added and stirred for an additional 30 minutes. The reaction mixture was 
loaded onto a Sephadex G-10 column and eluted with deionized water. The fractions with 
the product were identified using reverse phase HPLC and lyophilized to obtain 5AS (62 
mg, 0.18 mmol, 90%). 
1
H
 
NMR (D2O, 300 MHz) δ 2.50 (s, 3H, CH3), 3.78 (s, 3H, CH3), 
7.32 (s, 1H, Ar-H), 7.39 (s, 1H, Ar-H) (Figure 39). 
13
C NMR 13.60, 56.67, 104.48, 
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105.74, 113.99, 125.63, 137.24, 146.75, 148.54, 161.61, 172.44 (Figure 40). ESI (+ve) 
m/z calcd for C11H8Na2O8S [(M+H)
+
)] 346.97, found 347.15 (Figure 41). Capillary 
electropherogram (Figure 57A) 
2.5.8 Synthesis of 2A 
To a solution of 2E (50 mg, 0.2 mmol, 1.0 equiv) in EtOH (2 ml) in a 2-necked flask fitted 
with a condenser was added 2N NaOH (0.3 ml) and the mixture was heated to 80
0
C. After 
16 hours, the completion of the reaction indicated by TLC, the reaction mixture was cooled 
to room temperature and quenched, acidified with 2N HCl and extracted with ethyl acetate. 
The organic extract was dried (an. Na2SO4), concentrated in vacuo and purified using flash 
chromatography on silica gel (50% EtOAc in hexanes) to give 2A (40 mg, 0.18 mmol, 
90%). 
1
H NMR (CH3OD, 300 MHz) δ 2.66 (s, 3H, CH3), 3.88 (s, 3H, CH3), 7.05 (s, 1H, 
Ar-H), 7.32 (s, 1H, Ar-H) (Figure 42). 
13
C NMR 13.16, 55.51, 94.55, 106.08, 108.83, 
119.12, 144.00, 146.66, 148.03, 162.37, 166.49 (Figure 43). ESI (-ve) m/z calcd for 
C11H10O5 [(M-H)
-
)] 221.05, found 220.98 (Figure 44). Capillary electropherogram 
(Figure 57B) 
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Figure 36  
1
H NMR for 4AS 
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Figure 37  
13
C NMR for 4AS 
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Figure 38 ESI mss spectra for 4AS 
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Figure 39  
1
H NMR for 5AS 
 
 
 
c
O
O
O
O-Na+
d
b
H
HSO3
-Na+
Oa
  96 
Figure 40  
13
C NMR for 5AS 
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Figure 41 ESI mass spectra of 5AS 
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Figure 42  
1
H NMR for 2A 
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Figure 43 
13
C NMR for 2A 
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Figure 44 ESI mass spectra of 2A 
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2.5.9 Synthesis of 1X 
To a solution of LiAlH4 (15.18 mg, 0.4 mmol, 5.0 equiv) in THF (0.8 ml) was added 
compound 2E (20 mg, 0.08 mmol, 1.0 equiv) in THF (0.8 ml) drop wise, slowly under 
nitrogen. The reaction mixture was stirred for ten hours after which 6 μl of H2O, 6 μl of 15 
% w/v NaOH and 18 μl of H2O were added successively. Afterwards ethylacetate was 
added to the mixture and was stirred for 30 minutes. The crude was filtered over celite and 
dried (an. Na2SO4), concentrated in vacuo and purified on silica gel (0-40% EtOAc in 
hexanes) to obtain 1X (14 mg, 0.067 mmol, 84%, ). 
1
H
 
NMR (acetone-d6, 300 MHz) δ 2.35 
(s, 3H, CH3), 3.88 (s, 3H, CH3), 4.65 (s, 2H, CH2), 7.02 (s, 1H, Ar-H), 7.05 (s, 1H, Ar-H) 
(Figure 45). 
13
C NMR 10.87, 54.01, 55.52, 94.41, 103.66, 114.74, 121.31, 142.87, 145.14, 
147.50, 150.36 (Figure 46).     
 
2.5.10 Synthesis of 7E and 7ES 
To a solution of 2E (910 mg, 3.63 mmol, 1.0 equiv) in DMF (30 ml) was added imidazole 
(1.20 g, 18.15 mmol, 5.0 equiv) and TBDMSCl (3.2 g, 21.83 mmol, 6.0 equiv) and the 
mixture was stirred. After 16 hours the reaction mixture was diluted with water, extracted 
with diethyl ether and the organic extract was dried (an. Na2SO4), concentrated in vacuo 
and purified by flash chromatography on silica gel (0-15% EtOAc in hexanes) to obtain the 
silyl protected derivative (1.19 g, 3.26 mmol, 89%). 
A two-necked flask was charged with a solution of lithium aluminum hydride (520 mg, 
13.71 mmol, 5.0 equiv) in THF (27 ml). To this solution under an atmosphere of nitrogen 
was added in a dropwise manner (over a period of 20 minutes) a solution of the silyl 
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derivative (1.0 g, 2.74 mmol, 1.0 equiv) in THF (27 ml). The mixture was stirred for 16 
hours. After the completion of the reaction H2O (0.52 ml), 15% w/v aqueous NaOH (0.52 
ml) and H2O (1.56 ml) were sequentially added. Then, the reaction mixture was poured 
into diethyl ether and stirred for 30 minutes. The organic extract was filtered through 
celite, dried (an. Na2SO4), concentrated in vacuo and purified using flash chromatography 
on silica gel (10-30% EtOAc in hexanes) to give 9 (710 mg, 2.2 mmol, 80%). 
1
H NMR 
(CDCl3, 300 MHz) δ 0.14 (s, 6H, CH3), 1.01 (s, 9H, CH3), 2.41 (s, 3H, CH3), 3.82 (s, 3H, 
CH3), 4.69 (s, 2H, CH2), 6.93 (s, 1H, Ar-H), 7.01 (s, 1H, Ar-H) (Figure 47). 
To a solution of 9 (100 mg, 0.310 mmol, 1.0 equiv) in CH2Cl2 (3.1 ml) were added 
TEMPO (9.68 mg, 0.062 mmol, 0.2 equiv), tetrabutyl ammonium chloride (17.23 mg, 
0.062 mmol, 0.2 equiv), NaHCO3 solution (3.1 ml, 0.5 M) and N-chloro succinimide 
(124.18 mg, 0.93 mmol, 3.0 equiv). The reaction mixture was allowed to stir for 4 hours 
and after the completion of the reaction as indicated on TLC, the mixture was extracted 
with CH2Cl2 and water. The organic layer was dried (an. Na2SO4), concentrated in vacuo 
and purified using flash chromatography on silica gel (20% EtOAc in hexanes) to give 10 
(80 mg, 0.25 mmol, 81%). 
1
H NMR (CDCl3, 300 MHz) δ 0.16 (s, 6H, CH3), 1.01 (s, 9H, 
CH3), 2.71 (s, 3H, CH3), 3.84 (s, 3H, CH3), 6.95 (s, 1H, Ar-H), 7.54 (s, 1H, Ar-H), 10.15 
(s, 1H, CH) (Figure 48). 
 
A two necked flask fitted with a reflux condenser was charged with a solution of 10 (120 
mg, 0.374 mmol, 1.0 equiv) in benzene (2.5 ml). To this was added (carbethoxymethylene) 
triphenylphosphorane (196 mg, 0.562 mmol, 1.5 equiv) under an atmosphere of nitrogen. 
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The mixture was refluxed for 3.5 hours. Afterwards the reaction was brought to room 
temperature and was diluted with CH2Cl2. The mixture was concentrated in vacuo and 
purified by flash chromatography on silica gel (10% EtOAc in hexanes) to obtain the trans 
isomer (140 mg, 0.36 mmol, 96%). 
1
H NMR (CDCl3, 300 MHz) δ 0.16 (s, 6H, CH3), 1.03 
(s, 9H, CH3), 1.36 (t, J = 6Hz, 3H, CH3),  2.53 (s, 3H, CH3), 3.84 (s, 3H, CH3), 4.30 (q, J 
=9Hz, 2H, CH2), 6.36 (d, J =15Hz, 1H, CH),  6.95 (s, 1H, Ar-H), 7.18 (s, 1H, Ar-H), 7.77 
(d, J =18Hz, 1H, CH) (Figure 49). 
 
A solution of the trans isomer (230 mg, 0.588 mmol, 1.0 equiv) in ethanol (6 ml) was 
hydrogenated in Parr shaker apparatus over 46 mg of 10% Pd/C at room temperature and at 
an initial pressure of 35 psig over a period of 4 hours. The catalyst was removed by 
filtration over celite and washed with ether and acetone. The solvents were concentrated 
under vacuo to obtain 260 mg of the crude compound, which NMR indicated partial de-
silylation had occurred. Crude 12 was used for the next step without purification. 
To a solution of the crude 12 (176 mg, 1.0 equiv) in THF (2.61 ml) was added tetrabutyl 
ammonium fluoride in THF (1 M in THF, 1.79 ml, 4.0 equiv) and stirred for a period of 4 
hours. Afterwards the reaction was quenched with saturated ammonium chloride solution 
and extracted into EtOAc. The organic extract was concentrated in vacuo and purified 
using flash chromatography on silica gel to obtain 7E (130 mg, 0.47 mmol). 
1
H NMR 
(CDCl3, 300 MHz) δ 1.22 (t, J = 6Hz, 3H, CH3), 2.36 (s, 3H, CH3), 2.59 (t, J = 6Hz, 2H, 
CH2), 2.87 (t, J = 9Hz, 2H, CH2), 3.91 (s, 3H, CH3), 4.12 (q, J = 6Hz, 2H, CH2), 5.49 (s, 
1H, OH), 6.93 (s, 1H, Ar-H), 6.94 (s, 1H, Ar-H) (Figure 50). 
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To a solution of 7E (34 mg, 0.122 mmol, 1.0 equiv) in acetonitrile (0.42 ml) in a 
microwave tube were added triethylamine (0.16 ml, 1.22 mmol, 10 equiv) and 
trimethylamine-sulfur trioxide complex (136.0 mg, 0.977 mmol, 8.0 equiv) under nitrogen. 
The reaction mixture was exposed to microwaves (50 W, 30 min, 100
0
C). The mixture was 
concentrated in vacuo and purified by flash chromatography on silica gel (0-10% MeOH in 
DCM) and dried to give the triethylamine-sulfate salt. This was dissolved in 20% EtOH-
water and loaded onto a Sephadex C-25 column. Appropriate fractions were pooled and 
lyophilized to give 7ES (18mg, 0.047 mmol, 39%). 
1
H NMR (D2O, 300 MHz) δ 1.18 (t, J = 
6Hz, 3H, CH3), 2.34 (s, 3H, CH3), 2.62 (t, J = 9Hz, 2H, CH2), 2.87 (t, J = 9Hz, 2H, CH2), 
3.85 (s, 3H, CH3), 4.08 (q, J = 9Hz, 2H, CH2), 7.06 (s, 1H, Ar-H), 7.50 (s, 1H, Ar-H) 
(Figure 51). 
 
2.5.11 Synthesis of 7AS 
7ES (18 mg, 0.047 mmol, 1.0 equiv) was dissolved in DMSO (0.5 ml). To this solution 
were added potassium tert-butoxide (TCI AMERICA) (15.93 mg, 0.142 mmol, 3.0 equiv) 
and H2O (1.5 μl, 0.0705 mmol, 1.5 equiv) under nitrogen. The reaction was monitored on 
reverse phase HPLC and after 3 hours dibasic sodium phosphate (66.72 mg, 0.47 mmol, 
10.0 equiv) was added and stirred for an additional 30 minutes. The reaction mixture was 
loaded onto a Sephadex G-10 column and eluted with deionized water. The fractions with 
the product were identified using reverse phase HPLC, lyophilized to obtain 7AS (16 mg, 
0.043 mmol, 91%). 
1
H NMR (D2O, 300 MHz) δ 2.12 (s, 3H, CH3), 2.22 (t, J = 6Hz, 2H, 
CH2), 2.61 (t, J = 6Hz, 2H, CH2), 3.66 (s, 3H, CH3), 6.94 (s, 1H, Ar-H), 7.23 (s, 1H, Ar-H) 
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(Figure 52). ESI (+ve) m/z calcd for C13H12Na2O8S [(M+H)
+
)] 375.00, found 375.17 
(Figure 53). Capillary electropherogram (Figure 57A). 
 
2.5.12 Synthesis of 7A 
To a solution of 7E (27 mg, 0.097 mmol, 1.0 equiv) in EtOH (0.9 ml) in a 2-necked flask 
fitted with a condenser was added sodium hydroxide (0.15 ml from 2N soln) and the 
mixture was heated to 80
0
C. After 6 hours, the completion of the reaction indicated by 
TLC, the reaction mixture was cooled to room temperature and quenched, acidified with 
2N HCl and extracted with ethyl acetate. The organic extract was dried (an. Na2SO4) and 
concentrated in vacuo and  purified using flash chromatography on silica gel (5% MeOH 
in EtOAc) to give 7A (12 mg, 0.048 mmol, 50%).
 1
H NMR (CH3OD, 300 MHz) δ 2.32 (s, 
3H, CH3), 2.55 (t, J = 6Hz, 2H, CH2), 2.85 (t, J = 6Hz, 2H, CH2), 3.86 (s, 3H, CH3), 6.85 
(s, 1H, Ar-H), 6.98 (s, 1H, Ar-H) (Figure 54). 
13
C NMR 10.66, 19.10, 33.85, 55.59, 94.86, 
103.29, 112.66, 121.69, 142.80, 145.83, 148.28, 150.00 (note: one carbon missing 
probably because of an overlap) (Figure 55). ESI (-ve) m/z calcd for C13H14O5 [(M-H)
-
)] 
249.08, found 249.00 (Figure 56). Capillary electropherogram (Figure 57B). 
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Figure 45  
1
H NMR of 1X 
 
 
c
e
ad
O
HO
O
OH
b
H
H
  107 
 
Figure 46  
13
C NMR of 1X 
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Figure 47  
1
H NMR of compound 9 
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H NMR of compound 10 
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Figure 49  
1
H NMR of compound 11 
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Figure 50  
1
H NMR of compound 7E 
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Figure 51  
1
H NMR of compound 7ES 
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Figure 52  
1
H NMR of compound 7AS 
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Figure 53 ESI mass spectra of 7AS 
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Figure 54  
1
H NMR of compound 7A 
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Figure 55  
13
C NMR of compound 7A 
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Figure 56 ESI mass spectra of 7A 
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Figure 57A Capillary electropherogram’s for 4AS, 5AS, 6AS and 7AS 
 
Figure 57B Capillary electropherogram’s for 1A, 2A and 7A 
 
  119 
2.5.13 Direct Inhibition of factor Xa and thrombin (Work performed by Dr. Liang) 
Direct inhibition of thrombin and factor Xa by the benzofuran derivatives was determined 
using chromogenic substrate hydrolysis assays. The buffer used in these experiments was 20 
mM Tris-HCl buffer, pH 7.4, containing 100 mM NaCl, 2.5 mM CaCl2, and 0.1% 
polyethylene glycol (PEG) 8000. In these assays, 3 to 134 μL of a stock solution of 
benzofuran derivatives in DMSO was diluted with appropriate volume of the buffer in PEG 
20,000-coated polystyrene cuvettes to give 0.4 to 4.3 mM inhibitor concentration in a final 
incubation volume of 1000 μL. Then 5 μL of the stock enzyme solution was added to give 4.8 
nM thrombin or 1.1 nM factor Xa, followed by 20 μL of 1 mM Spectrozyme TH or 100 μL of 
4.1 mM S-2772. The residual enzyme activity was determined from the initial rate of increase 
in absorbance at 405 nm. Control experiments with DMSO without the benzofuran derivative 
were performed to assess the loss of enzyme activity. Relative residual proteinase activity (in 
%) at each concentration of the benzofuran derivative was calculated as a ratio of the slopes 
measured in the presence of the inhibitor to that in its absence. 
 
2.5.14 Michaelis-Menten Kinetics of S-2772 Hydrolysis by Factor Xa in the Presence 
of 5AS (Work performed by Dr. Liang) 
The initial rate of S-2772 hydrolysis by 1.1 nM factor Xa was monitored from the linear 
increase in absorbance at 405 nm. The initial rate was measured as a function of various 
concentrations of substrate S-2772 (20.5–492.0 μM) in the presence of 2.6 mM 5AS in 20 
mM Tris-HCl buffer, pH 7.4, containing 100 mM NaCl, 2.5 mM CaCl2, and 0.1% PEG8000 
at 25 °C. The data were fitted by the Michaelis-Menten equation to determine KM and VMAX. 
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CHAPTER 3 Virtual screening of the synthesized β-5 like Compounds  
 
 
3.1 Rationale 
Designing non-sugar heparin mimics that recognize targets like antithrombin, thrombin 
and fXa is a major challenge. Non-sugar scaffolds bearing multiple sulfate and carboxylate 
groups of high chain length, e.g., of the size of heparin, are difficult to model. Modeling 
such scaffolds is fraught with problems of specificity because of the surface exposed, 
shallow heparin-binding sites on proteins with high density of positively charged residues, 
which induces recognition of practically any collection of negative charges in these 
molecules. Our lab had earlier designed the dual filter strategy for ligand docking using 
GOLD, which consists of an ―affinity‖ and ―specificity‖ filter. This strategy successfully 
reproduced the binding geometry of a crystallized sequence–specific heparin 
pentasaccharide to within 2.5 Å for antithrombin-heparin interaction
143
. 
Results described in chapter 2 show that selected β-5 like molecules inhibit fXa. Moreover, 
a slight preference for the benzofuran scaffold was observed for inhibition of fXa when 
compared to thrombin. 
We sought to explore if the GOLD-based protocol of ligand docking, which was developed 
for antithrombin-heparin interaction would help in our case, i.e., for explaining the 
observed inhibition profile of the synthesized β-5 like molecules against factor Xa. 
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Furthermore, kinetic studies showed that these molecules inhibit fXa by an allosteric 
mechanism of action. Based on the structural domains present in fXa, the synthesized β-5 
like molecules would bind to the exosite-II in fXa. Therefore, it was an important point to 
elucidate how these molecules interact with the exosite-II in fXa, and which residues of the 
exosite-II are involved in binding.    
 
3.2 Coordinates for the synthesized β-5 like molecules 
The seven synthesized molecules which were observed to inhibit fXa; 1A, 2A, 4AS, 5AS, 
6AS and 7AS, were drawn in SYBYL. The atom type of sulfur and oxygen atoms in SO3 
was modified to S.o2 and O.co2, and the atom type for oxygen and carbon in   
carboxylates was modified to O.co2 and O.Co2 respectively. The bond type between these 
atoms was modified to aromatic. Each of the compounds in the library was minimized 
using the Tripos force field with Gasteiger-Hückel charges, a fixed dielectric constant of 
80, and a nonbonded cutoff radius of 8 Å. Minimization was carried out for a maximum of 
10000 iterations subject to a termination gradient of 0.05 kcal/(mol.A). 
 
3.3 Protein coordinates 
The exosite in fXa is a surface-exposed, shallow, solvent exposed surface lined by basic 
residues. Therefore, to define the binding site on fXa in GOLD, wherein the genetic 
algorithm (GA) can sample all possible conformations of the ligand, the cavity detection 
algorithm in GOLD cannot be used. This is because the exosite-II is not a hydrophobic 
cavity where a ligand can be docked. Therefore, the binding site must be defined using a 
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ligand in the bound site which implies it is crystallized with the protein. However, no 
crystal structure has been deposited in the PDB with a ligand crystallized on the exosite-II 
of fXa.  
Yet, seven of the basic residues present on the exosite-II in fXa are conserved in thrombin 
also
2
. These residues are Arg
93
, Lys
96
, Arg
125
, Arg
165
, Lys
169
, Lys
236
 and Arg
240
. 
Additionally, the crystal structure of thrombin in complex with heparin octasaccharide was 
available
144
 (PDB code 1XMN). Thus, fXa
98
 (PDB code 1HCG) and thrombin were 
aligned by homology. The seven basic residues in the exosite-II of thrombin were spatially 
found to be similar in orientation in fXa (Figure 58). 
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Figure 58 Thrombin and fXa aligned by homology. The seven basic exosite-II 
residues in fXa are conserved in thrombin. The blue ribbon is fXa and the magenta is 
thrombin. 
`  
 
 
The next step in defining the binding site in GOLD was to place the heparin 
hexasaccharide crystallized with thrombin onto the same site of fXa. Thus, the coordinates 
of the heparin hexasaccharide were extracted and placed on the aligned structure of fXa 
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and the binding site in GOLD was defined as 16 Å from every atom in the hexasaccharide 
(Figure 59). This definition of the binding site covers all important known heparin binding 
residues in fXa. 
 
Figure 59 The binding site defined on fXa in GOLD. The binding site is shown as a 
solid surface colored by lipophillic potential. Green represents hydrophilic surface and red 
shows hydrophobic surface. 
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3.4  Docking of β-5 like synthesized molecules onto fXa 
The docking of seven synthesized compound, onto fXa was done by GOLD 4.0. GOLD is 
a soft docking method that allows a small degree of interpenetration, or van der waals 
overlap of ligand and protein atoms. GOLD also optimizes the positions of hydrogen-bond 
donating atoms on Ser, Thr, Tyr and Lys residues as part of the docking process
146
. For 
docking, the specificity screen developed in our lab was used. This involves screening of 
all possible sequences using 300000 genetic algorithm (GA) iterations, which is 
collectively termed as one GA run. This ensures sampling of the entire conformational 
space available in the predefined binding site of fXa. Here, GOLD starts with a population 
of 100 arbitrarily docked ligand orientations and evaluates them using the GA fitness 
function, which assigns them a GOLD score and improves their fitness by an iterative 
optimization procedure that is biased towards higher scores. The initial population is 
selected at random; hence several such runs are required to consistently predict bound 
conformations. 10 GA runs were used in this study with the GOLD score to evaluate the 
fitness and 10 such runs are collectively termed as one docking experiment. Furthermore, 
the GA was set to preterminate if the top two ranked solutions came within 2.5 A RMSD 
and the top two ranked solutions are saved. The docking was driven using the GOLD 
scoring function. The final analysis of the computed solutions was done using the modified 
GOLD score, which was found to correlate well with antithrombin binding affinities for 
pentasaccharide variants
143
.  
Modified GOLD score = HBEXT + 1.375 × VDWEXT 
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Where HBEXT and VDWEXT are the ―external‖ (nonbonded interactions between the ligand 
and the receptor) hydrogen bonding and van der waals respectively. 
The docking experiments were run in triplicate to ensure greater confidence in docked 
geometries. The top two solutions resulting from these runs (from each experiment) were 
considered for further analysis. Hence, a triplicate docking experiment would yield a 
maximum of six solutions. The RMSD between the six computed solutions were compared 
and convergence of these 3 independent experiments is observed if the RMSD matrix 
displays a set of 6 solutions within 2.5 Å of each other, indicating a high affinity-
specificity sequence. Specificity here suggests a preference for a defined binding 
geometry; wherein a particular sequence among the entire set of compounds can recognize 
the protein binding site in a single, well-defined binding mode. Hence, all the seven 
compounds which displayed inhibitory potential were docked using the adapted docking 
algorithm developed in our lab (Figure 60). 
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Figure 60  Docking algorithm used for present study (adapted from Raghuraman 
et.al; J. Med. Chem. 2006, 49, 3553-3562) . 
START
Build and Minimize 
compounds
Specificity Screen
300,000 GA iterations, three 
runs per molecule
RMSD ≤ 2.5A?
 High-Specificity Sequence(s)
END
DISCARD
YES
NO
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3.5 GOLD explains the observed inhibition profile of the monomers 
 
Out of the seven compounds, which were docked in triplicate, five of them (2A, 4AS, 5AS, 
6AS and 7AS) were found to exhibit high specificity, i.e., the RMSD matrix indicated that 
RMSD difference between the computed docked poses of the experiments ran in triplicate 
came within 2.5 Å. Inspection of the computed binding mode of these 5 compounds 
revealed that two of these compounds (5AS and 6AS) bind in exactly the same manner 
interacting with the same residues (Lys
236
, Arg
125
, Lys 
230
, Gln
178
) that came within 
hydrogen bonding distance (Figure 61A and 61B). 
 
Figure 61A The docked pose of 5AS on exosite-II of fXa. The red lines indicate 
hydrogen bonds 
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Figure 61B Overlay of the docked poses of 5AS and 6AS 
 
 Interestingly, these two compounds, 5AS and 6AS, were found to inhibit fXa 86% and 
75% respectively at 2.6 mM. Inspection of the docked pose of compound 4AS, which is a 
regioisomer of 5AS, indicates that it adopts a totally different docked pose on the exosite-II 
of fXa with interacting only with Arg
125
, Lys
230
 and  Gln
178
. (Figure 62A) 
 
Figure 62A The docked pose of 4AS. The red lines indicate hydrogen bonds  
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This likely explains why 4AS inhibits fXa much weaker (42% at 2.6 mM) when compared 
to 5AS (86% at 2.6 mM) and 6AS (75% at 2.6 mM). 4AS cannot adopt the docked pose 
assumed by 5AS and 6AS, because if 4AS is overlaid on 5AS and 6AS, the sulfate can 
interact with Arg
125
, Lys
230
 and Gln
178
. However, the carboxylate on position-3 of 4AS 
does not have any residue to interact with, so 4AS assumes a different docked pose that 
5AS and 6AS (Figure 62B) 
 
Figure 62B Overlay of docked poses of 4AS, 5AS and 6AS 
 
  
Going over of the docked pose of 2A indicates that it adopts a totally different 
conformation on the protein. Only the carboxylate on the position-3 of the ring interacts 
with the backbone nitrogen of  Lys
236
 (Figure 63). 
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Figure 63 Docked pose of 2A on fXa. Red lines indicate hydrogen bonds  
 
The only interaction observed between 2A and fXa is just one hydrogen bond between the 
carboxylate and Lys
236
. This explains the much weaker inhibition of fXa observed by 2A 
(34% at 2.6 mM). 
Compound 7AS adopts a quite interesting pose on fXa. The 5-O-SO3 is seen to interact 
with Arg
125
, Gln
178
 and Lys
230
. Moreover, the extended carboxylate linker interacts with 
the backbone nitrogen of Lys
236
 (Figure 64A). 
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Figure 64A Docked pose of 7AS. The red lines indicate hydrogen bonds   
 
 
When this pose of 7AS is overlaid with the docked poses of 5AS and 6AS, interesting 
observations can be made (Figure 64B).   
7AS has a docked pose almost similar to 5AS and 6AS. The sulfate interacts with the same 
residues as which 5AS and 6AS interact but, the carboxylate is poised on the other side and 
because of the extended linker; it is able to interact with the backbone nitrogen of Lys
236
. 
This difference in the docked pose explains the weaker inhibition exhibited by 7AS (39% 
at 2.6 mM).  
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Figure 64B Overlay of docked poses of 7AS, 5AS and 6AS.  
 
3.6 Discussion 
The design of allosteric inhibitors of fXa is a challenging task because of the inadequate 
information of the exact binding site to be targeted and due to lack of robust computational 
methods to solve this problem. Overall, we have the idea that the exosite-II in fXa is lined 
by arginines and lysines, but which factors generate specificity is an ongoing debate. 
Screening of our synthesized β-5 like monomers against fXa, generates some information 
about which residues in the exosite-II play a critical role in driving specificity in binding. 
Looking for any specific compounds in the bioactive synthesized series, only 5 molecules 
were found to bind specifically, which are 2A, 4AS, 5AS, 6AS and 7AS. Interestingly, the 
most active compounds in the series, 4AS, 5AS and 6AS were found to exhibit higher 
specificity and affinity. Observing the calculated docked poses of the most potent 
molecules in this series, 5AS and 6AS drives some interesting conclusions. Both of these 
compounds are seen to interact with residues Lys
236
, Arg
125
, Lys 
230 
and Gln
178
. The 5-
OSO3 group in compound 5AS is seen to interact with no residue in the protease. Having a 
  134 
common pharmacophore i.e. the 6-OSO3 and the 3-COO
-
 among these compounds and 
both being docked consistently on the exosite-II supports and explains the observed 
inhibition profile of these compounds. Furthermore, the regioisomer of 5AS, which is 4AS 
having a much weaker inhibitory potential was found to be interesting during the 
biological evaluation of these compounds, as it was found to inhibit fXa much weaker than 
what was observed for 5AS. The docked pose of 4AS, 5AS and 6AS supports the 
biochemical study. In addition, it supports the preferential recognition hypothesis, as can 
be seen that 4AS interacts with Arg
125
, Lys
230
 and Gln
178
. The absence of the common 
pharmacophore in 4AS seen in 5AS and 6AS renders 4AS incapable of making any 
interaction with Lys
236
. Moreover, the 3-COO
-
 is not seen to interact with any residue in 
the protease explaining its weaker inhibitory profile. 
Compound 2A is seen to interact only with Lys
236
. This explains why 2A inhibits the 
protease much weakly. Inspection of the docked pose of 7AS overlaid with 5AS and 6AS 
is exciting. The 5-OSO3
-
 interacts with Arg
125
, Lys 
230 
and Gln
178
. However, the 
carboxylate with the extended linker cannot assume a conformation such that it interacts 
with the side chain of Lys
236. The carboxylate is observed to make contacts with the 
backbone nitrogen of Lys
236
. This explains the weaker inhibitory profile observed for this 
compound.  
A careful examination of what residues in the exosite-II of fXa drive specificity show that 
the most potent compounds in the series (5AS and 6AS) interact with Lys
236
, Arg
125
, Lys 
230 
and Gln
178
. Also, all the other compounds that were found to be specific in GOLD 
screening are seen to interact with the same above mentioned residues, but not necessarily 
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with all of them. Hence, a pharmacophore, which can interact with all the above mentioned 
residues, should be designed for displaying allosteric inhibition towards fXa. 
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CHAPTER 4 Summary and Significance  
 
A large number of inhibitors have been designed to target either fXa or thrombin. Nearly 
all of these compounds act as competitive inhibitors that target the active site of the 
proteases. However, nature favors a strategy that involves targeting the exosites on these 
coagulation proteases and inhibiting them. Examples being; heparin that binds to the 
exosite-II of thrombin and fXa and other peptides extracted from blood sucking leeches, 
which also target the exosite of these proteases. So, evolutionarily this seems like preferred 
tactic wherein exosites were evolved on these proteases for the modulation of their 
function.    But, small molecules that act as allosteric inhibitors of factor Xa and thrombin 
are unknown and the molecules studied here are the first example of such allosteric 
inhibitors. 
The molecules synthesized here are based on the β-5 like scaffold of CDSO3 and sulfates 
and carboxylates were introduced differentially on them to target the exosite-II of thrombin 
and fXa. The inhibition profile of these compounds indicated a preference for the β-5 like 
scaffold for fXa over thrombin. Docking of these compounds on the exosite-II of fXa 
explained the relevance of the pharmacophore that was extracted from the inhibition 
profile.  
These compounds were found to display inhibition of thrombin and fXa in the millimolar 
range, which is fairly high. However, this is not too unexpected as these compounds are 
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fairly small and have suboptimal binding features. Michealis-Menten kinetics indicated an 
allosteric mechanism of enzyme inhibition, which is similar to the lead CDSO3.  
Considering that the exosite-II in fXa and thrombin is 15-20Å long, the inhibition profile 
exhibited by these compounds is quite promising. Moreover, the lead CDSO3 consists of 
5-13 monomeric units and possible involves multiple dihydrobenzofuran and 
phenoxypropanoic acid units to generate the observed nanomolar affinity. The coupling of 
the most potent compounds in this study 5AS and 6AS with phenoxypropanoic acid units, 
which are found in CDSO3 would result in radically different molecules from the known 
ligands with high affinity. 
Furthermore, the design of allosteric inhibitors for fXa and thrombin is difficult due to the 
inadequate information of the important residues critical for binding and the mode of 
binding. This inadequacy is amplified with heparin mimics because of the highly surface 
exposed interaction involving electrostatic interactions. Yet, the novel allosteric 
mechanism of these small synthetic molecules affords the opportunity to discover new 
molecules with possibly different pharmacological and toxicological profile. Thus, the 
synthetic molecules designed on the basis of CDSO3 scaffold may result in potent 
functional mimics of heparin.   
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APPENDIX A 
 
Abbreviations used: APC, activated protein C; AT, antithrombin; APTT, activated partial 
thromboplastin time; CA, caffeic acid; CEMTPP, (carbethoxy) methylene triphenyl 
phosphorane; CD, dehydropolymer of caffeic acid; CDSO3, sulfated dehydropolymer of 
caffeic acid; DEFGH, antithrombin-binding heparin pentasaccharide sequence; DHP, 
dehydrogenation polymer; DIBAL, diisobutylaluminum hydride; DMSO, dimethyl 
sulfoxide; GOLD, genetic optimization for ligand docking; HIT, heparin induced 
thrombocytopenia; HMWK, high molecular weight kininogen; HRP, horseradish 
peroxidase; IC50, concentration of inhibitor that results in 50% inhibition; LAH, lithium 
aluminum hydride; LMWH, low molecular weight heparin; MMTPP, methoxymethylene 
triphenyl phosphorane; Mw, weight average molecular weights; PT, prothrombin time; 
RCL, reactive center loop; RMSD, root mean squared deviation; TEMPO, 2,2,6,6-
Tetramethylpiperidine-1-oxyl; TFPI, tissue factor pathway inhibitor; UFH, unfractionated 
heparin. 
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